Aemetis (AMTX) 10-Q 8 Aug 22 2022 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2022	Jul. 31, 2022
Cover [Abstract]
Entity Registrant Name	AEMETIS, INC.
Entity Central Index Key	0000738214
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Small Business	false
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Jun. 30, 2022
Entity Filer Category	Accelerated Filer
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022
Entity Common Stock Shares Outstanding		34,584,207
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-36475
Entity Incorporation State Country Code	DE
Entity Tax Identification Number	26-1407544
Entity Interactive Data Current	Yes
Entity Address Address Line 1	20400 Stevens Creek Blvd
Entity Address Address Line 2	Suite 700
Entity Address City Or Town	Cupertino
Entity Address State Or Province	CA
Entity Address Postal Zip Code	95014
City Area Code	408
Local Phone Number	213-0940
Security 12b Title	Common Stock, $0.001 par value
Trading Symbol	AMTX
Security Exchange Name	NASDAQ

CONSOLIDATED CONDENSED BALANCE

CONSOLIDATED CONDENSED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents ($18 and $19 respectively from VIE)	$ 3,558	$ 7,751
Accounts receivable, net of allowance for doubtful accounts of $0 and $1,404 as of June 30, 2022 and December 31, 2021, respectively	1,278	1,574
Inventories, net of allowance for excess and obsolete inventory of $1,040 as of June 30, 2022 and December 31, 2021, respectively	4,905	5,126
Prepaid expenses ($184 and $335 respectively from VIE)	4,752	5,598
Other current assets	552	644
Total current assets	15,045	20,693
Property, plant and equipment, net ($54,992 and $39,625 respectively from VIE)	156,790	135,101
Operating lease right-of-use assets ($0 and $10 respectively from VIE)	2,294	2,462
Other assets ($537 and $38 respectively from VIE)	4,323	2,575
Total assets	178,452	160,831
Current liabilities:
Accounts payable ($6,942 and $4,950 respectively from VIE)	19,138	16,415
Current portion of long term debt	9,003	8,192
Short term borrowings ($9 and $9 respectively from VIE)	15,856	14,586
Mandatorily redeemable Series B convertible preferred stock	3,915	3,806
Accrued property taxes ($0 and $121 respectively from VIE)	984	6,830
Accrued contingent litigation fees	0	6,200
Current portion of operating lease liability ($5 and $11 respectively from VIE)	258	260
Current portion of Series A preferred units ($4,608 and $3,169 respectively from VIE)	4,608	3,169
Other current liabilities ($777 and $306 respectively from VIE)	6,600	5,872
Total current liabilities	60,362	65,330
Long term liabilities:
Senior secured notes and revolving notes	140,084	121,451
EB-5 notes	32,000	32,500
Other long term debt ($36 and $40 respectively from VIE)	11,665	12,038
Series A preferred units ($50,280 and $44,978 respectively from VIE)	50,280	44,978
Operating lease liability	2,191	2,318
Other long term liabilities	4,583	2,454
Total long term liabilities	240,803	215,739
Stockholders' deficit:
Series B convertible preferred stock, $0.001 par value; 7,235 authorized; 1,270 and 1,275 shares issued and outstanding each period, respectively (aggregate liquidation preference of $3,810 and $3,825 respectively)	1	1
Common stock, $0.001 par value; 80,000 authorized; 34,582 and 33,461 shares issued and outstanding each period, respectively	35	33
Additional paid-in capital	221,915	205,305
Accumulated deficit	(339,730)	(321,227)
Accumulated other comprehensive loss	(4,934)	(4,350)
Total stockholders' deficit	(122,713)	(120,238)
Total liabilities and stockholders' deficit	$ 178,452	$ 160,831

CONSOLIDATED CONDENSED BALANC_2

CONSOLIDATED CONDENSED BALANCE SHEETS (Parenthetical) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Allowance For Doubtful Accounts	$ 0	$ 1,404,000
Inventory Valuation Reserves	$ 1,040,000	$ 1,040,000
Common Stock, Par Value	$ 0.001	$ 0.001
Common Stock, Shares Authorized (in Thousands)	80,000,000	80,000,000
Common Stock, Shares Issued (in Thousands)	34,582,000	33,461,000
Common Stock, Shares Outstanding (in Thousands)	34,582,000	33,461,000
Short Term Borrowings	$ 15,856,000	$ 14,586,000
Series B Convertible Preferred Stock
Series B Preferred Stock, Par Value	$ 0.001	$ 0.001
Series B Preferred Stock, Authorized (in Thousands)	7,235,000	7,235,000
Series B Preferred Stock, Shares Issued (in Thousands)	1,270,000	1,275,000
Series B Preferred Stock, Shares Outstanding (in Thousands)	1,270,000	1,275,000
Aggregate Liquidation Preference	$ 3,810,000	$ 3,825,000
Variable Interest Entity, Primary Beneficiary [Member]
Cash And Cash Equivalents, Vie	18,000	19,000
Prepaid Expenses, Vie	184,000	335,000
Property, Plant And Equipment, Vie	54,992,000	39,625,000
Operating Lease Right-of-use Assets, Vie	0	10,000
Other Assets, Vie	537,000	38,000
Accounts Payable, Vie	6,942,000	4,950,000
Short Term Borrowings	9,000	9,000
Accrued Property Taxes	0	121,000
Current Portion Of Operating Lease Liability, Vie	5,000	11,000
Current Portion Of Series A Preferred Units, Vie	4,608,000	3,169,000
Other Current Liabilities, Vie	777,000	306,000
Other Long Term Debt, Vie	36,000	40,000
Series A Preferred Units, Vie	$ 50,280,000	$ 44,978,000

CONSOLIDATED CONDENSED STATEMEN

CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) (Unaudited)
Revenues	$ 65,901	$ 54,884	$ 117,950	$ 97,691
Cost of goods sold	66,115	51,238	121,249	97,653
Gross profit (loss)	(214)	3,646	(3,299)	38
Research and development expenses	51	21	87	44
Selling, general and administrative expenses	7,061	5,753	14,367	11,135
Other operating expense	360	0	360	0
Operating loss	(7,686)	(2,128)	(18,113)	(11,141)
Interest expense
Interest rate expense	4,928	4,529	9,363	10,494
Debt related fees and amortization expense	1,740	690	3,566	1,905
Accretion and other expenses of Series A preferred units	1,506	3,800	3,146	5,743
Gain on debt extinguishment	0	(1,134)	0	(1,134)
Gain on litigation	(1,400)	0	(1,400)	0
Other expense (income)	(14,254)	544	(14,295)	513
Loss before income taxes	(206)	(10,557)	(18,493)	(28,662)
Income tax expense	3	0	10	7
Net loss	(209)	(10,557)	(18,503)	(28,669)
Other comprehensive loss
Foreign currency translation loss	(390)	(184)	(584)	(209)
Comprehensive loss	$ (599)	$ (10,741)	$ (19,087)	$ (28,878)
Net loss per common share
Basic	$ (0.01)	$ (0.34)	$ (0.54)	$ (1)
Diluted	$ (0.01)	$ (0.34)	$ (0.54)	$ (1)
Weighted average shares outstanding
Basic	34,536	30,924	34,128	28,781
Diluted	34,536	30,924	34,128	28,781

CONSOLIDATED CONDENSED STATEM_2

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Operating activities:
Net loss	$ (18,503)	$ (28,669)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation	3,389	1,116
Depreciation	2,661	2,764
Debt related fees and amortization expense	3,566	1,905
Intangibles and other amortization expense	23	24
Accretion and other expenses of Series A preferred units	3,146	5,743
Loss on asset disposals	47	0
Gain on debt extinguishment	0	(1,134)
Gain on litigation	(1,400)	0
Loss on lease termination	736	0
Provision for bad debts	0	144
Changes in operating assets and liabilities:
Accounts receivable	294	(70)
Inventories	187	(610)
Prepaid expenses	2,138	(4,393)
Other assets	(1,647)	2,588
Accounts payable	392	(2,711)
Accrued interest expense and fees	8,542	4,361
Other liabilities	(10,054)	729
Net cash used in operating activities	(6,483)	(18,213)
Investing activities:
Capital expenditures	(22,518)	(12,935)
Grant proceeds and other reimbursements received for capital expenditures	6,147	1,224
Net cash used in investing activities	(16,371)	(11,711)
Financing activities:
Proceeds from borrowings	30,622	0
Repayments of borrowings	(16,191)	(53,523)
Lender debt renewal and waiver fee payments	(869)	0
Grant proceeds received for capital expenditures	0	115
Payments on finance leases	(182)	(247)
Proceeds from issuance of common stock in equity offering	5,124	86,319
Proceeds from the exercise of stock options	201	1,032
Proceeds from Series A preferred units financing	0	3,130
Series A preferred financing redemption	0	(300)
Net cash provided by financing activities	18,705	36,526
Effect of exchange rate changes on cash and cash equivalents	(44)	(19)
Net change in cash and cash equivalents for period	(4,193)	6,583
Cash and cash equivalents at beginning of period	7,751	592
Cash and cash equivalents at end of period	3,558	7,175
Supplemental disclosures of cash flow information, cash paid:
Cash paid for interest	14,270	5,425
Income taxes paid	10	7
Supplemental disclosures of cash flow information, non-cash transactions:
Subordinated debt extension fees added to debt	340	340
Debt fees added to revolving lines	500	0
Fair value of warrants issued to subordinated debt holders	1,393	281
Fair value of warrants issued for guarantee fees	2,012	0
Fair value of warrants issued to lender for debt issuance costs	3,158	0
Fair value of stock issued to lender	1,335	0
Lender debt extension, waiver, and other fees added to debt	583	1,215
Capital expenditures in accounts payable	10,230	4,948
Payment of debt added to revolving lines	16,266	0
Financing lease liabilities arising from obtaining right of use assets	2,932	0
Capital expenditures purchased on financing	0	55
Issuance of equity to pay off accounts payable	$ 0	$ 893

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS DEFICIT (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Series B Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss
Balance, shares at Dec. 31, 2020		1,323	22,830
Balance, amount at Dec. 31, 2020	$ (184,744)	$ 1	$ 23	$ 93,426	$ (274,080)	$ (4,114)
Issuance of common stock, shares			5,682
Issuance of common stock, amount	62,395	0	$ 6	62,389	0	0
Stock options exercised, shares			1,226
Stock options exercised, amount	1,003	0	$ 1	1,002	0	0
Stock-based compensation	835	0	$ 0	835	0	0
Issuance and exercise of warrants, shares			113
Issuance and exercise of warrants, amount	281	0	$ 0	281	0	0
Foreign currency translation loss	(25)	0	0	0	0	(25)
Net loss	(18,112)	$ 0	$ 0	0	(18,112)	0
Balance, shares at Mar. 31, 2021		1,323	29,851
Balance, amount at Mar. 31, 2021	(138,367)	$ 1	$ 30	157,933	(292,192)	(4,139)
Balance, shares at Dec. 31, 2020		1,323	22,830
Balance, amount at Dec. 31, 2020	(184,744)	$ 1	$ 23	93,426	(274,080)	(4,114)
Stock-based compensation	1,116
Net loss	(28,669)
Balance, shares at Jun. 30, 2021		1,323	31,572
Balance, amount at Jun. 30, 2021	(124,024)	$ 1	$ 32	183,015	(302,749)	(4,323)
Balance, shares at Mar. 31, 2021		1,323	29,851
Balance, amount at Mar. 31, 2021	(138,367)	$ 1	$ 30	157,933	(292,192)	(4,139)
Issuance of common stock, shares			976
Issuance of common stock, amount	24,774	0	$ 1	24,773	0	0
Stock options exercised, shares			745
Stock options exercised, amount	29	0	$ 1	28	0	0
Stock-based compensation	281	0	0	281	0	0
Foreign currency translation loss	(184)	$ 0	$ 0	0	0	(184)
Net loss	(10,557)				(10,557)
Balance, shares at Jun. 30, 2021		1,323	31,572
Balance, amount at Jun. 30, 2021	(124,024)	$ 1	$ 32	183,015	(302,749)	(4,323)
Balance, shares at Dec. 31, 2021		1,275	33,461
Balance, amount at Dec. 31, 2021	(120,238)	$ 1	$ 33	205,305	(321,227)	(4,350)
Issuance of common stock, shares			341
Issuance of common stock, amount	3,349	0	$ 1	3,348	0	0
Stock options exercised, shares			263
Stock options exercised, amount	196	0	$ 0	196	0	0
Stock-based compensation	2,040	0	$ 0	2,040	0	0
Issuance and exercise of warrants, shares			113
Issuance and exercise of warrants, amount	4,550	0	$ 0	4,550	0	0
Foreign currency translation loss	(194)	0	0	0	0	(194)
Net loss	(18,294)	$ 0	$ 0	0	(18,294)	0
Series B conversion to common stock, shares		(5)	1
Series B conversion to common stock, amount	0	$ 0	$ 0	0	0	0
Balance, shares at Mar. 31, 2022		1,270	34,179
Balance, amount at Mar. 31, 2022	(128,591)	$ 1	$ 34	215,439	(339,521)	(4,544)
Balance, shares at Dec. 31, 2021		1,275	33,461
Balance, amount at Dec. 31, 2021	(120,238)	$ 1	$ 33	205,305	(321,227)	(4,350)
Stock-based compensation	3,389
Net loss	(18,503)
Balance, shares at Jun. 30, 2022		1,270	34,582
Balance, amount at Jun. 30, 2022	(122,713)	$ 1	$ 35	221,915	(339,730)	(4,934)
Balance, shares at Mar. 31, 2022		1,270	34,179
Balance, amount at Mar. 31, 2022	(128,591)	$ 1	$ 34	215,439	(339,521)	(4,544)
Issuance of common stock, shares			400
Issuance of common stock, amount	5,124	0	$ 1	5,123	0	0
Stock options exercised, shares			3
Stock options exercised, amount	4	0	$ 0	4	0	0
Stock-based compensation	1,349	0	0	1,349	0	0
Foreign currency translation loss	(390)	0	0	0	0	(390)
Net loss	(209)	$ 0	$ 0	0	(209)	0
Balance, shares at Jun. 30, 2022		1,270	34,582
Balance, amount at Jun. 30, 2022	$ (122,713)	$ 1	$ 35	$ 221,915	$ (339,730)	$ (4,934)

Nature of Activities and Summar

Nature of Activities and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Nature of Activities and Summary of Significant Accounting Policies
Nature Of Activities And Summary Of Significant Accounting Policies	1. Nature of Activities and Summary of Significant Accounting Policies We own and operate a 65 million gallon per year ethanol production facility located in Keyes, California (the “Keyes Plant”). In addition to low carbon renewable fuel ethanol, the Keyes Plant produces Wet Distillers Grains (“WDG”), Distillers Corn Oil (“DCO”), and Condensed Distillers Solubles (“CDS”), all of which are sold as animal feed to local dairies and feedlots. In the fourth quarter of 2021, an ethanol zeolite membrane dehydration system was installed at the Keyes Plant and is in the process of being commissioned, a key first step in the electrification of the Keyes Plant. During 2018, Aemetis Biogas, LLC (“ABGL”) was formed to construct bio-methane anaerobic digesters at local dairies near the Keyes Plant, many of whom also purchase WDG produced at the Keyes Plant. The digesters are connected via an underground private pipeline owned by ABGL to a gas cleanup and compression unit being built at the Keyes Plant to produce dairy renewable natural gas (“RNG”). Upon receiving the bio-methane from the dairies, impurities are removed, and the bio-methane is converted to negative carbon intensity RNG that will either be injected into the statewide PG&E gas utility pipeline, supplied as compressed RNG that will service local trucking fleets, or used as renewable process energy at the Keyes Plant. Our Dairy Renewable Natural Gas segment, comprised of ABGL, has completed Phase 1 of our California biogas digester network and pipeline system that converts waste dairy methane gas into RNG, including two operational dairies and seven miles of pipeline. ABGL is now executing Phase 2 construction with the completion of sixteen miles of pipeline and the commissioning of the biogas-to-RNG upgrade unit at the Keyes Plant as well as beginning construction of additional dairy digesters. During the second quarter of 2022, Aemetis has completed construction of a third dairy digester and commissioning of the centralized gas cleanup facility and utility gas interconnect located at the Keyes Plant where dairy biogas will be upgraded to RNG and injected into the utility pipeline. Upon receiving pathway certification from the California Air Resources Board (CARB), the fuel is expected to be delivered into the Northern California gas delivery system. Our ‘Carbon Zero’ biofuels production plants are designed to produce biofuels, including sustainable aviation fuel (“SAF”) and diesel fuel utilizing renewable hydrogen and non-edible renewable oils sourced from existing Aemetis biofuels plants and other sources. The first plant to be built, in Riverbank, California, “Carbon Zero 1”, is expected to utilize hydroelectric and other renewable power available onsite to produce 90 million gallons per year of SAF, renewable diesel, and other byproducts. The plant is expected to supply the aviation and truck markets with ultra-low carbon renewable fuels to reduce GHG emissions and other pollutants associated with conventional petroleum-based fuels. By producing ultra-low carbon renewable fuels, the Company expects to capture higher value D3 Renewable Identification Numbers (“RINs”) and California’s LCFS credits. D3 RINs have a higher value in the marketplace than D6 RINs due to D3 RINs’ relative scarcity and mandated pricing formula from the United States Environmental Protection Agency (“EPA”). On April 1, 2021, we established Aemetis Carbon Capture, Inc. to build Carbon Capture and Sequestration (CCS) projects to generate LCFS and IRS 45Q credits by injecting CO₂ into wells which are monitored for emissions to ensure the long-term sequestration of carbon underground. The CCS projects are expected to capture and sequester up to two million metric tons per year of CO₂ at the two Aemetis biofuels plant sites in Keyes and Riverbank, California. In July 2022, Aemetis purchased 24 acres, on the Riverbank Industrial Complex site in Riverbank, California, to develop a CCS injection well. The Company plans to construct a characterization well to obtain both the data and well design information required for the EPA Class VI CO₂ injection well permit application. The well is expected to sequester up to one million metric tons per year of CO₂. We also own and operate a production facility on the East Coast of India (the “Kakinada Plant”) with a nameplate capacity of 150 thousand metric tons per year, or about 50 million gallons per year, producing high quality distilled biodiesel and refined glycerin for customers in India and Europe. The Kakinada Plant is capable of processing a variety of vegetable oils and animal fat waste feedstocks into biodiesel that meet international product standards. The Kakinada Plant also distills the crude glycerin byproduct from the biodiesel refining process into refined glycerin, which is sold to the pharmaceutical, personal care, paint, adhesive and other industries. Basis of Presentation and Consolidation. All intercompany balances and transactions have been eliminated in consolidation. The accompanying consolidated condensed balance sheet as of June 30, 2022, the consolidated condensed statements of operations and comprehensive income (loss) for the three and six months ended June 30, 2022 and 2021, the consolidated condensed statements of cash flows for the six months ended June 30, 2022 and 2021, and the consolidated condensed statements of stockholders’ deficit for the three and six months ended June 30, 2022 and 2021 are unaudited. The consolidated condensed balance sheet as of December 31, 2021 was derived from the 2021 audited consolidated financial statements and notes thereto. The consolidated condensed financial statements in this report should be read in conjunction with the 2021 audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2021. The accompanying consolidated condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. In the opinion of Company’s management, the unaudited interim consolidated condensed financial statements as of and for the three and six months ended June 30, 2022 and 2021 have been prepared on the same basis as the audited consolidated statements as of and for the year ended December 31, 2021 and reflect all adjustments, consisting primarily of normal recurring adjustments, necessary for the fair presentation of its statement of financial position, results of operations and cash flows. The results of operations for the three and six months ended June 30, 2022 are not necessarily indicative of the operating results for any subsequent quarter, for the full fiscal year or any future periods. Use of Estimates Revenue Recognition California Ethanol: The below table shows our sales in our California Ethanol segment by product category: For the three months ended June 30, For the six months ended June 30, 2022 2021 2022 2021 Ethanol and high-grade alcohol sales $ 47,656 $ 42,169 $ 85,551 $ 72,089 Wet distiller's grains sales 15,150 10,630 26,666 21,665 Other sales 3,085 1,931 5,715 3,304 $ 65,891 $ 54,730 $ 117,932 $ 97,058 We have elected to adopt the practical expedient that allows for ignoring the significant financing component of a contract when estimating the transaction price when the transfer of promised goods to the customer and customer payment for such goods are expected to be within one year of contract inception. Further, we have elected to adopt the practical expedient in which incremental costs of obtaining a contract are expensed when the amortization period would otherwise be less than one year. We also assessed principal versus agent criteria as we buy our feedstock from our customers and process and sell finished goods to those customers in certain contractual agreements. For our California Ethanol segment, we buy corn as feedstock for the production of ethanol, from our working capital partner J.D. Heiskell. Prior to May 13, 2020, we sold all our ethanol, WDG, and corn oil to J.D. Heiskell and we bought all our corn to process into ethanol from J.D. Heiskell. After May 13, 2020, we sold most of our fuel ethanol to one customer, Kinergy, and sold all WDG and corn oil to J.D. Heiskell. During the second quarter of 2021, we signed a biofuels offtake agreement with Murex, and beginning on October 1, 2021 we sold all our fuel ethanol to Murex. We only have customer relationships with Kinergy and Murex, hence the principal and agent criteria are not applied. However, we are still buying corn and selling WDG and corn oil to J.D.Heiskell. We analyzed the principal versus agent relationship criteria below. We consider the purchase of corn as a cost of goods sold and the sale of WDG and, corn oil, upon trucks leaving the Keyes Plant, as revenue on the basis that (i) we control and bear the risk of gain or loss on the processing of corn which is purchased at market prices into ethanol and (ii) we have legal title to the goods during the processing time. The pricing for both WDG and corn oil is set independently. Revenues from WDG and corn oil are billed net of the related transportation and marketing charges. The transportation component is accounted for in cost of goods sold and the marketing component is accounted for in sales, general and administrative expense. Transportation and marketing charges are known within days of the transaction and are recorded at the actual amounts. We have elected an accounting policy under which these charges have been treated as fulfillment activities provided after control has transferred. As a result, these charges are recognized in cost of goods sold and selling, general and administrative expenses, respectively, when revenue is recognized. Revenues are recorded at the gross invoiced amount. Hence, we are the principal in California Ethanol segment where our customer and vendor may be the same. Dairy Renewable Natural Gas: India Biodiesel: The below table shows our sales in our India Biodiesel Segment by product category: For the three months ended June 30, For the six months ended June 30, 2022 2021 2022 2021 Biodiesel sales $ - $ 107 $ - $ 465 Refined glycerin sales - 9 - 125 Other sales 10 38 18 43 $ 10 $ 154 $ 18 $ 633 In India, we also assessed principal versus agent criteria as we buy our feedstock from our customers and process and sell finished goods to those same customers in certain contractual agreements. In those cases, we receive the legal title to feedstock from our customers once it is on our premises. We control the processing and production of biodiesel based on contract terms and specifications. The pricing for both feedstock and biodiesel is set independently. We hold the title and risk to biodiesel according to agreements when we enter into in these situations. Hence, we are the principal in India sales scenarios where our customer and vendor may be the same. Cost of Goods Sold Shipping and Handling Costs. Research and Development. Cash and Cash Equivalents. Accounts Receivable. The Company maintains an allowance for doubtful accounts for balances that appear to have specific collection issues. The collection process is based on the age of the invoice and requires attempted contacts with the customer at specified intervals. If, after a specified number of days, the Company has been unsuccessful in its collection efforts, a bad debt allowance is recorded for the balance in question. Delinquent accounts receivables are charged against the allowance for doubtful accounts once un-collectability has been determined. The factors considered in reaching this determination are the apparent financial condition of the customer and the Company’s success in contacting and negotiating with the customer. If the financial condition of the Company’s customers were to deteriorate, additional allowances may be required. We reserved $1.4 million in the allowances for doubtful accounts as of December 31, 2021 and wrote off the balances as uncollectible during the second quarter of 2022. Inventories Variable Interest Entities. Property, Plant and Equipment The Company evaluates the recoverability of long-lived assets with finite lives in accordance with ASC Subtopic 360-10-35 Property Plant and Equipment—Subsequent Measurements, California Energy Commission Low-Carbon Fuel Production Program California Department of Food and Agriculture Dairy Digester Research and Development Grant In October 2020, the Company was awarded $7.8 million in matching grants from the CDFA Dairy Digester Research and Development program. The CDFA grant reimburses the Company for costs required to permit and construct six of the Company’s biogas capture systems under contract with central California dairies. The Company has received $1.6 million from the CDFA 2020 grant program as of June 30, 2022, as reimbursement for actual costs incurred. Due to the uncertainty associated with the approval process under the grant program, the Company recognized the grant as a reduction of costs in the period when payment is received. California Energy Commission Low Carbon Advanced Ethanol Grant Program. U.S. Department of Food and Agriculture Forest Service Grant. California Energy Commission Grant for Solar Microgrid, DSC and Battery Backup System. California Department of Forestry and Fire Protection Grant. California Department of Forestry and Fire Protection Grant. U.S Forest Service Community Wood Grant. USDA’s Biofuel Producer Program Grant. Basic and Diluted Net Loss per Share. The following table shows the number of potentially dilutive shares excluded from the diluted net loss per share calculation as of June 30, 2022 and 2021: As of June 30, 2022 June 30, 2021 Series B preferred (post split basis) 127 132 Common stock options and warrants 4,748 4,252 Debt with conversion feature at $30 per share of common stock 1,228 1,273 Total number of potentially dilutive shares excluded from the diluted net (loss) per share calculation 6,103 5,657 Comprehensive Income (Loss). Comprehensive Income (Loss) Foreign Currency Translation/Transactions. Segments. The “California Ethanol” reportable segment includes the Company’s 65 million gallon per year Keyes plant and the adjacent land leased for the production of CO₂. The “Dairy Renewable Natural Gas” reportable segment include, the dairy digesters, pipeline and gas condition hub for the production of biogas from dairies near Keyes, California. The “India Biodiesel” reportable segment includes the Company’s 50 million gallon per year nameplate capacity biodiesel manufacturing Kakinada Plant, the administrative offices in Hyderabad, India, and the holding companies in Nevada and Mauritius. The Company’s biodiesel is marketed and sold primarily to customers in India through brokers and by the Company directly. The Company has additional operating segments that were determined not to be reportable segments, including the Carbon Zero 1 facility in Riverbank, the Goodland Plant in Kansas and the research and development facility in Minnesota. Refer to the “All Other” category. Fair Value of Financial Instruments. Commitments and Contingencies. Contingencies Convertible Instruments Debt Modification Accounting Debt–Modification and Extinguishments For a complete summary of the Company’s significant accounting policies, please refer to the Company’s audited financial statements and notes thereto for the years ended December 31, 2021 and 2020 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 10, 2022.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2022
Inventories
Inventories	2. Inventories Inventories consist of the following: As of June 30, 2022 December 31, 2021 Raw materials $ 903 $ 727 Work-in-progress 2,522 2,083 Finished goods 1,480 2,316 Total inventories $ 4,905 $ 5,126 As of June 30, 2022, and December 31, 2021, the Company recognized a lower of cost or net realizable value impairment of $165 thousand and none respectively, related to inventory.

Property Plant and Equipment

Property Plant and Equipment	6 Months Ended
	Jun. 30, 2022
Property Plant and Equipment
Property, Plant And Equipment	3. Property, Plant and Equipment Property, plant and equipment consist of the following: As of June 30, 2022 December 31, 2021 Land $ 6,156 $ 4,082 Plant and buildings 122,165 97,110 Furniture and fixtures 1,504 1,334 Machinery and equipment 5,203 5,294 Tenant improvements 56 - Construction in progress 51,279 55,859 Property held for development 15,437 15,437 Finance lease right of use assets 3,152 2,317 Total gross property, plant & equipment 204,952 181,433 Less accumulated depreciation (48,162 ) (46,332 ) Total net property, plant & equipment $ 156,790 $ 135,101 For the three months ended June 30, 2022 and 2021, interest capitalized in property, plant, and equipment was $2.6 million and $0.9 million, respectively. For the six months ended June 30, 2022 and 2021, interest capitalized in property, plant, and equipment was $4.7 million and $1.5 million, respectively. Construction in progress includes costs for the biogas construction projects (dairy digesters and pipeline), Riverbank projects (sustainable aviation fuel and renewable diesel plant as well as carbon capture characterization well), and energy efficiency projects at the Keyes Plant. Depreciation on the components of property, plant and equipment is calculated using the straight-line method to allocate their depreciable amounts over their estimated useful lives as follows: Years Plant and buildings 20 - 30 Machinery and equipment 5 - 15 Furniture and fixtures 3 - 5 For the three months ended June 30, 2022 and 2021, the Company recorded depreciation expense of $1.3 million and $1.4 million, respectively. For the six months ended June 30, 2022 and 2021, the Company recorded depreciation expense of $2.7 million and $2.8 million, respectively.

Debt

Debt	6 Months Ended
	Jun. 30, 2022
Debt
Debt	4. Debt Debt consists of the following: June 30, 2022 December 31, 2021 Third Eye Capital term notes $ 7,089 $ 7,095 Third Eye Capital revolving credit facility 54,039 75,980 Third Eye Capital revenue participation term notes 11,912 11,915 Third Eye Capital acquisition term notes 26,464 26,461 Third Eye Capital Fuels Revolving Line 18,393 - Third Eye Capital Carbon Revolving Line 22,187 - Cilion shareholder seller notes payable 6,718 6,619 Subordinated notes 15,105 14,304 EB-5 promissory notes 41,004 40,692 Term loans on capital expenditures 5,697 5,701 Total debt 208,608 188,767 Less current portion of debt 24,859 22,778 Total long term debt $ 183,749 $ 165,989 Third Eye Capital Note Purchase Agreement On July 6, 2012, Aemetis, Inc. and Aemetis Advanced Fuels Keyes, Inc. (“AAFK”), entered into an Amended and Restated Note Purchase Agreement (the “Note Purchase Agreement”) with Third Eye Capital Corporation (“Third Eye Capital”). Pursuant to the Note Purchase Agreement, Third Eye Capital extended credit in the form of (i) senior secured term loans in an aggregate principal amount of approximately $7.2 million to replace existing notes held by Third Eye Capital (the “Term Notes”); (ii) senior secured revolving loans in an aggregate principal amount of $18.0 million (the “Revolving Credit Facility”); (iii) senior secured term loans in the principal amount of $10.0 million to convert the prior revenue participation agreement to a note (the “Revenue Participation Term Notes”); and (iv) senior secured term loans in an aggregate principal amount of $15.0 million (the “Acquisition Term Notes”) used to fund the cash portion of the acquisition of Cilion, Inc. (the Term Notes, Revolving Credit Facility, Revenue Participation Term Notes and Acquisition Term Notes are referred to herein collectively as the “Original Third Eye Capital Notes”). On February 27, 2019, a promissory note (the “February 2019 Note”, together with the Original Third Eye Capital Notes, the “Third Eye Capital Notes”) for $2.1 million was advanced by Third Eye Capital to Aemetis, Inc., as a short-term credit facility for working capital and other general corporate purposes with an interest rate of 14% per annum maturing on the earlier of (a) receipt of proceeds from any financing, refinancing, or other similar transaction, (b) extension of credit by Third Eye Capital, as lender or as agent on behalf of certain lenders, to the Company or its affiliates, or (c) April 30, 2019. In consideration of the February 2019 Note, $0.1 million of the total proceeds were paid to Third Eye Capital as financing charges. On April 30, 2019, the February 2019 Note was modified to remove the stated maturity date and instead be due on demand by Third Eye Capital. In third quarter of 2019, the February 2019 Note was modified to include additional borrowings of $0.7 million. In first quarter of 2020, the February 2019 Note was modified to include additional borrowings of $0.6 million. The February 2019 note was fully repaid in the first quarter of 2021. On March 14, 2021, Third Eye Capital agreed to Limited Waiver and Amendment No. 19 to the Note Purchase Agreement (“Amendment No. 19”), to (i) provide for a waiver of the ratio of note indebtedness covenant for the quarter ended December 31, 2021, (ii) provide for a waiver of the consolidated unfunded capital expenditures covenant for the quarters through March 31, 2021. As consideration for such amendment and waivers, the borrowers also agreed to pay Third Eye Capital an amendment and waiver fee of $0.1 million in cash (the “Amendment No. 19 Fee”). We gave the notice to extend the maturity date of the Notes to April 1, 2022 and the extension fee equal to 1% of the Note Indebtedness in respect to each Note, provided that half of such fee may be added to the outstanding principal balance of each Note on the effective date of each such extension and rest of the balance may be payable in cash or common stock within 60 days of the date of such relevant extension. We evaluated the terms of the Amendment No. 19 and the maturity date extension and applied modification accounting treatment in accordance with ASC 470-50 Debt – Modification and Extinguishment. On August 9, 2021, Third Eye Capital agreed to the Limited Waiver and Amendment No. 20 to the Note Purchase Agreement (“Amendment No. 20”) to: (i) provide that, upon written notice to Third Eye Capital, the maturity date may be further extended to April 1, 2023 in exchange for an extension fee equal to 1% of the Note Indebtedness in respect of each Note, where half of such fee may be added to the outstanding principal balance of each Note on the effective date of each such extension; (ii) provide for a waiver of the ratio of note indebtedness covenant for the quarters ended March 31, 2022, June 30, 2022, September 30, 2022 and December 31, 2022; and (iii) provide for a waiver of the unfunded capital expenditures covenant for the quarter ended June 30, 2021 in which the Company exceeded the $100,000 capital expenditures limit. As consideration for such amendment and waivers, the borrowers also agreed to pay Third Eye Capital an amendment and waiver fee of $0.3 million in cash. We evaluated the terms of the Amendment No.20 and applied modification accounting treatment in accordance with ASC 470-50 Debt – Modification and Extinguishment. In the first quarter of 2022, the Company exercised the option to extend the maturity of Third Eye Capital Notes to April 1, 2023. On November 5, 2021, Third Eye Capital agreed to the Limited Waiver and Amendment No. 21 to the Note Purchase Agreement (“Amendment No. 21”) to: (i) provide a waiver for the Blocked Account Agreement Violation in which the Borrowers failed to deliver Blocked Account Control Agreements by August 31, 2021 and (ii) provide for a waiver for the Subordinated Debt Violation, in which the Company made a repayment to a Subordinated Debt lender. As consideration for such amendment and waivers, the borrowers also agreed to pay Third Eye Capital an amendment and waiver fee of $0.1 million in cash. We will evaluate the terms of the Amendment No.21 in accordance with ASC 470-50 Debt – Modification and Extinguishment. On March 8, 2022, Third Eye Capital agreed to the Limited Waiver and Amendment No. 22 to the Note Purchase Agreement (“Amendment No. 22”) to: (i) provide a waiver for the Blocked Account Agreement Violation in which the Borrowers failed to deliver Blocked Account Control Agreements by December 31, 2021, (ii) provide for a waiver for the Subordinated Debt Violation, in which the Company made a repayment to a Subordinated Debt lender, and (iii) provide for a waiver of the consolidated unfunded capital expenditures covenant for the quarters through December 31, 2021. As consideration for such waivers, the borrowers also agreed to pay Third Eye Capital an amendment and waiver fee of $0.1 million in cash. On May 11, 2022, Third Eye Capital agreed to the Limited Waiver and Amendment No. 23 to the Note Purchase Agreement (“Amendment No. 23”) to: (i) provide a waiver for the Blocked Account Agreement Violation in which the Borrowers failed to deliver Blocked Account Control Agreements by March 31, 2022, (ii) provide for a waiver of the ratio of note indebtedness covenant for the quarter ended March 31, 2023 and (iii) provide for a waiver of the unfunded capital expenditures covenant for the quarter ended March 31, 2022 in which the Company exceeded the $100,000 capital expenditures limit. As consideration for such amendment and waivers, the borrowers also agreed to pay Third Eye Capital an amendment and waiver fee of $0.1 million. As Amendments No. 19, No. 20, No. 21, No. 22, and No. 23 waived certain covenants for the quarters ended June 30, 2022, September 30, 2022, December 31, 2022, and March 31, 2023. According to ASC 470-10-45 Debt–Other Presentation Matters, if it is probable that the Company will not be able to cure the default at measurement dates within the next 12 months, the related debt needs to be classified as current. To assess this guidance, the Company performed ratio and cash flow analysis using its cash flow forecast and debt levels. The Company forecasted sufficient cash flows over the next 12 months to reduce debt levels of Third Eye Capital and meet operations of the Company. Based on this analysis, the Company believes that it is reasonably possible that through a combination of cash flows from operations, sales from EB-5 investments, and proceeds from the sale of common stock, it will be able to meet the ratio of the note indebtedness covenant over the next 12 months. As such, the notes are classified as long-term debt. On March 6, 2020, we and a subsidiary entered into a one-year reserve liquidity facility governed by a promissory note, payable to Third Eye Capital, in the principal amount of $18 million. On March 14, 2021, Third Eye Capital agreed to increase the amount available under the reserve liquidity facility to $70.0 million. Borrowings under the reserve liquidity facility are available from March 14, 2021 until maturity on April 1, 2023. Interest on borrowed amounts accrues at a rate of 30% per annum, paid monthly in arrears and may be capitalized and due upon maturity, or 40% if an event of default has occurred and continues. The outstanding principal balance of the indebtedness evidenced by the promissory note, plus any accrued but unpaid interest and any other sums due thereunder, shall be due and payable in full at the earlier to occur of (a) receipt by the Company or its affiliates of proceeds from any sale, merger, equity or debt financing, refinancing or other similar transaction from any third party and (b) April 1, 2023. Any amounts may be re-borrowed up to repaid amounts up until the maturity date of April 1, 2023. The promissory note is secured by liens and security interests upon the property and assets of the Company. In return, the Company will pay a non-refundable standby fee at 2% per annum of the difference between the aggregate principal amount outstanding and the commitment, payable monthly in cash. In addition, if any initial advances are drawn under the facility, the Company will pay a non-refundable one-time fee in the amount of $0.5 million provided that such fee may be added to the principal amount of the promissory note on the date of such initial advance. On August 9, 2021, Third Eye Capital agreed to decrease the amount available under the reserve liquidity notes governed by a promissory note to $40.0 million. Terms of Third Eye Capital Notes A. Term Notes. B. Revolving Credit Facility C. Revenue Participation Term Notes . D. Acquisition Term Notes E. Reserve Liquidity Notes * The note maturity date can be extended by the Company to April 2024. As a condition to any such extension, the Company would be required to pay a fee of 1% of the carrying value of the debt of which 50% can be paid in cash and 50% can be added to the outstanding debt. As a result of this ability to extend the maturity at the Company’s will, the Third Eye Capital Notes are classified as non-current debt. The Third Eye Capital Notes contain various covenants, including but not limited to, debt to plant value ratio, minimum production requirements, and restrictions on capital expenditures. The terms of the Third Eye Capital Notes allow the lender to accelerate the maturity in the occurrence of any event that could reasonably be expected to have a material adverse effect on the Company, such as any change in the business, operations, or financial condition. The Company has evaluated the likelihood of such an acceleration event and determined such an event to not be probable in the next twelve months. The terms of the notes allow interest to be capitalized. The Third Eye Capital Notes are secured by first priority liens on all real and personal property of, and assignment of proceeds from all government grants and guarantees from the Company’s North American subsidiaries. The Third Eye Capital Notes all contain cross-collateral and cross-default provisions. McAfee Capital, LLC (“McAfee Capital”), owned by Eric McAfee, the Company’s Chairman and CEO, provided a guaranty of payment and performance secured by all of its Company shares. In addition, Eric McAfee provided a blanket lien on substantially all of his personal assets, and McAfee Capital provided a guarantee in the amount of $8.0 million. GAFI Term Loan and Revolving Loan. Third Eye Capital Revolving Credit Facility for Fuels and Carbon Lines. As of June 30, 2022, GAFI had $20.2 million in principal and interest outstanding net of $1.9 million unamortized debt issuance costs. As of June 30, 2022, ACCI had $25.1 million in principal and interest outstanding net of $2.9 million in unamortized debt issuance costs. Cilion shareholder seller notes payable Subordinated Notes On January 1, 2022, the maturity on two Subordinated Notes’ was extended until the earlier of (i) June 30, 2022; (ii) after the occurrence of an Event of Default, including failure to pay interest or principal when due and breaches of note covenants. A $90 thousand and $250 thousand cash extension fee was paid by adding the fee to the balance of the new Subordinated Notes and 113 thousand common stock warrants were granted with a term of two years and an exercise price of $0.01 per share. The Company evaluated the January 1, 2022 amendment and the refinancing terms of the notes and applied modification accounting treatment in accordance with ASC 470-50 Debt – Modification and Extinguishment. At June 30, 2022 and December 31, 2021, the Company had, in aggregate, the amount of $15.1 million and $14.3 million in principal and interest outstanding, respectively, under the Subordinated Notes. EB-5 promissory notes The Company has sold an aggregate principal amount of $36.0 million of EB-5 Notes under the EB-5 Phase I funding since 2012 to the date of this filing. As of June 30, 2022, $35.5 million has been released from the escrow amount to the Company, with $0.5 million remaining to be funded to escrow. As of June 30, 2022 and December 31, 2021, $32.5 million in principal and $4.3 million in accrued interest and $32.5 million in principal and $4.1 million in accrued interest was outstanding, respectively, on the EB-5 Notes sold under the EB-5 Phase I funding. On October 16, 2016, the Company launched its EB-5 Phase II funding (the “EB-5 Phase II Funding”), with plans to issue $50.0 million in additional EB-5 Notes on substantially similar terms and conditions as those issued under the Company’s EB-5 Phase I funding, to refinance indebtedness and capital expenditures of Aemetis, Inc. and Goodland Advanced Fuels Inc., (“GAFI”). On November 21, 2019, the minimum investment was raised from $0.5 million per investor to $0.9 million per investor. The Company entered into a Note Purchase Agreement dated with Advanced BioEnergy II, LP, a California limited partnership authorized as a Regional Center to receive EB-5 Phase II funding investments, for the issuance of up to 100 EB-5 Notes bearing interest at 3%. On May 1, 2020 Supplement No. 3 amended the offering documents and lowered the total eligible new EB-5 Phase II funding investors to 60. Eight EB-5 investors have funded at the $0.5 million per investor amount, with 52 new EB-5 Phase II funding investors remaining eligible at the new $0.9 million per investors amount under the current offering. Job creation studies show it may be possible to add additional investors and increase the total offering amount in the future. Each EB-5 note will be issued in the principal amount and due and payable five years from the date of each EB-5 note, for a total aggregate principal amount of up to $50.8 million. The Company has sold an aggregate principal amount of $4.0 million of EB-5 Notes under the EB-5 Phase II funding since 2016 to the date of this filing. As of June 30, 2022, $4.0 million has been released from escrow to the Company and $46.8 million remains to be funded to escrow. As of June 30, 2022, $4.2 million was outstanding on the EB-5 Notes under the EB-5 Phase II funding. Secunderabad Oils Operating Agreement. Financing Agreement for capital expenditures. Scheduled debt repayments for the Company’s loan obligations by year are as follows: Twelve Months ended June 30, Debt Repayments 2023 $ 24,859 2024 132,218 2025 26,191 2026 29,473 2027 944 There after 1,169 Total debt 214,854 Debt issuance costs (6,246 ) Total debt, net of debt issuance costs $ 208,608

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies
Commitments And Contingencies	5. Commitments and Contingencies Leases We have identified assets as the corporate office, warehouse, monitoring equipment and laboratory facilities over which we have control and obtain economic benefits fully. We classified these identified assets as operating leases after assessing the terms under classification guidance. We have entered into several leases for trailers and carbon units with purchase option at the end of the term. We have concluded that it is reasonably certain that we would exercise the purchase option at the end of the term, hence the leases were classified as finance leases. All of our leases have remaining term of less than a year to 15 years. We made an accounting policy election to keep leases with an initial term of 12 months or less off of the balance sheet. We will recognize those lease payments in the Consolidated Statements of Operations as we incur the expenses. When discount rates implicit in leases cannot be readily determined, the Company uses the applicable incremental borrowing rate at lease commencement to perform lease classification tests on lease components and measure lease liabilities and right-of-use (“ROU”) assets. The incremental borrowing rate used by the Company was based on weighted average baseline rates commensurate with the Company’s secured borrowing rate over a similar term. At each reporting period, when there is a new lease initiated, the rates established for that quarter will be used. On December 14, 2021, we entered into a real estate purchase agreements and lease disposition and development agreement with the City of Riverbank. We plan to utilize the purchased and leased properties, located at 5300 Claus Road in the city of Riverbank, California, for the construction of the Carbon Zero 1 Facility. The lease commenced on April 1, 2022. The Company evaluated the lease in accordance with ASC 842 – Lease Accounting and classified the lease as a finance lease. The components of lease expense and sublease income were as follows: Three Months ended June 30, Six Months ended June 30, 2022 2021 2022 2021 Operating lease cost Operating lease expense $ 159 $ 204 $ 347 $ 408 Short term lease expense 75 71 102 110 Variable lease expense 23 21 46 54 Total operating lease cost $ 257 $ 296 $ 495 $ 572 Finance lease cost Amortization of right-of-use assets $ 28 $ 55 $ 89 $ 110 Interest on lease liabilities 99 20 119 41 Total finance lease cost $ 127 $ 75 $ 208 $ 151 Cash paid for amounts included in the measurement of lease liabilities: Three Months ended June 30, Six Months ended June 30, 2022 2021 2022 2021 Operating cash flows used in operating leases $ 174 $ 173 $ 338 $ 340 Operating cash flows used in finance leases 99 20 118 41 Financing cash flows used in finance leases 50 124 $ 182 248 Supplemental non-cash flow information related to ROU asset and lease liabilities was as follows for the three and six months ended June 30, 2022 and 2021: Three Months ended June 30, Six Months ended June 30, 2022 2021 2022 2021 Operating leases Accretion of the lease liability $ 85 $ 96 $ 179 $ 195 Amortization of right-of-use assets 74 108 168 213 Weighted Average Remaining Lease Term Operating leases 5.9 years Finance leases 14.1 years Weighted Average Discount Rate Operating leases 14.0 % Finance leases 13.4 % Supplemental balance sheet information related to leases was as follows: June 30, 2022 December 31, 2021 Operating leases Operating lease right-of-use assets $ 2,294 $ 2,462 Current portion of operating lease liability 258 260 Long term operating lease liability 2,191 2,318 Total operating lease liabilities 2,449 2,578 Finance leases Property and equipment, at cost $ 3,152 $ 2,317 Accumulated depreciation (72 ) (376 ) Property and equipment, net 3,080 1,941 Other current liability 196 550 Other long term liabilities 2,849 720 Total finance lease liabilities 3,045 1,270 Maturities of operating lease liabilities were as follows: Twelve months ended June 30, Operating leases Finance leases 2023 $ 572 $ 561 2024 581 279 2025 599 179 2026 617 151 2027 636 145 There after 606 11,000 Total lease payments 3,611 12,315 Less imputed interest (1,162 ) (9,270 ) Total lease liability $ 2,449 $ 3,045 The Company acts as sublessor in certain leasing arrangements, primarily related to land and buildings. Fixed sublease payments received are recognized on a straight-line basis over the sublease term. Sublease income and head lease expense for these transactions are recognized on a gross basis on the consolidated financial statements. This was recorded in the other operating income section of the Consolidated Statements of Operations and Comprehensive Loss. The components of lease income for the three and six months ended June 30, 2022 and June 30, 2021 were as follows: June 30, 2022 June 30, 2021 Lease income $ 377 $ - Future lease commitments to be received by the Company as of June 30, 2022 were as follows: Twelve months ended June 30, 2023 $ 830 2024 686 2025 541 2026 474 2027 474 There after 1,303 Total future lease commitments $ 4,308 Property taxes On March 3, 2022, the Company paid $6.1 million to Stanislaus County for property taxes past due. Legal Proceedings On August 31, 2016, the Company filed a lawsuit in Santa Clara County Superior Court against defendant EdenIQ, Inc. (“EdenIQ”). The lawsuit was based on EdenIQ’s wrongful termination of a merger agreement that would have effectuated the merger of EdenIQ into a new entity that would be primarily owned by Aemetis. On July 24, 2019, the court awarded EdenIQ a portion of the fees and costs it had sought in the amount of approximately $6.2 million and the Company recorded these fees based on the court order. On May 6, 2022 the parties settled the dispute for $4.8 million by entering into a settlement agreement. The settlement was paid and a gain on litigation of $1.4 million was recognized on the income statement in the second quarter of 2022.

Aemetis Biogas LLC - Series A P

Aemetis Biogas LLC - Series A Preferred Financing and Variable Interest Entity	6 Months Ended
	Jun. 30, 2022
Aemetis Biogas LLC - Series A Preferred Financing and Variable Interest Entity
Biogas Llc - Series A Preferred Financing	6. Aemetis Biogas LLC – Series A Preferred Financing and Variable Interest Entity On December 20, 2018, ABGL entered into a Series A Preferred Unit Purchase Agreement for the sale of Series A Preferred Units to Protair-X Americas, Inc., with Third Eye Capital acting as an agent. ABGL is authorized to issue 11,000,000 common units, and up to 6,000,000 convertible, redeemable, secured, preferred membership units (the “Series A Preferred Units”). ABGL issued 6,000,000 common units to the Company at $5.00 per common unit for a total of $30,000,000 in funding. Additionally, 5,000,000 common units of ABGL are held in reserve as potential conversion units issuable to the Purchaser upon certain triggering events discussed below. The Preferred Unit Agreement includes (i) preference payments of $0.50 per unit on the outstanding Series A Preferred Units commencing on the second anniversary, with any outstanding preference payments shall have an interest per annum rate equal to ten percent (ii) conversion rights for up to 1,200,000 common units or up to maximum number of 5,000,000 common units (also at a one Series A Preferred Unit to one common unit basis) if certain triggering events occur, (iv) one board seat of the three available to be elected by Series A Preferred Unit holders, (iii) mandatory redemption value at $15 per unit payable at an amount equal to 75% of free cash flow generated by ABGL, up to $90 million in the aggregate (if all units are issued), (iv) full redemption of the units on the sixth anniversary, (v) minimum cash flow requirements from each digester, and (vi) $0.9 million paid as fees to the Agent from the proceeds. Until paid, the obligations of ABGL under the Preferred Unit Agreement are secured by the assets of ABGL in an amount not to exceed the sum of (i) $30,000,000, plus (ii) all interest, fees, charges, expenses, reimbursement obligations and indemnification obligations of ABGL. Triggering events occur upon ABGL’s failure to redeem units, comply with covenants, any other defaults or cross defaults, or to perform representations or warranties. Upon a triggering event: (i) the obligation of the Purchaser to purchase additional Series A Preferred Units is terminated, (ii) cash flow payments for redemption payments increases from 75% to 100% of free cash flows, and (iii) total number of common units into which preferred units may be converted increases from 1,200,000 common units to 5,000,000 common units on a one for one basis. As of June 30, 2022, ABGL has not generated minimum quarterly operating cash flows by operating the dairies. As a result of the violation of this covenant, free cash flows, when they occur, may be applied for redemption payments at the increased rate of 100% instead of the initial rate of 75% of free cash flows. From inception of the agreement to date, ABGL issued 3,200,000 Series A Preferred Units on first tranche for a value of $16.0 million and also issued 2,800,000 of Series A Preferred Units on second tranche for a value of $14.0 million, reduced by a redemption of 20,000 Series A Preferred Units for $0.3 million. The Company is accreting these two tranches to the redemption value of $89.7 million over the estimated future cash flow periods of six years using the effective interest method. In addition, the Company identified freestanding future tranche rights and the accelerated redemption feature related to a change in control provision as derivatives which required bifurcation. These derivative features were assessed to have minimal value as of June 30, 2022 and December 31, 2021 based on the evaluation of the other conditions included In the agreement. In the three months ended March 31, 2021, ABGL issued 626,000 of Series A Preferred Units for incremental proceeds of $3.1 million as part of the second tranche of the Preferred Unit Agreement and redeemed 20,000 of Series A Preferred Units for $0.3 million. Consistent with the previous issuances which were treated as a liability as the conversion option was deemed to be non-substantive, the current issuances are treated as a liability as the conversion option was still deemed to be non-substantive. The Company recorded Series A Preferred Unit liabilities, net of unit issuance costs and inclusive of accretive preference pursuant to this agreement, and accrued preference payments, classified as current portion of Series A Preferred Units, of $4.6 million and $3.2 million, and long-term liabilities of $50.3 million and $45.0 million as of June 30, 2022 and December 31, 2021, respectively. Variable interest entity assessment After consideration of ABGL’s operations and the above agreement, we concluded that ABGL did not have enough equity to finance its activities without additional subordinated financial support. ABGL is capitalized with Series A Preferred Units that are recorded as liabilities under U.S. GAAP. Hence, we concluded that ABGL is a VIE. Through the Company’s ownership interest in all of the outstanding common stock, its current ability to control the board of directors, the management fee paid to Aemetis and control of subordinated financing decisions, Aemetis has been determined to be the primary beneficiary and accordingly, the assets, liabilities, and operations of ABGL are consolidated into those of the Company. Total assets, before intercompany eliminations, of ABGL as of June 30, 2022 were $57.8 million primarily related to biodigesters at three dairies, the gas conditioning hub, and a pipeline which serve as collateral for the Series A Preferred Unit totaling $54.9 million. The Series A Preferred Units are not collateralized by any other assets or guarantees from Aemetis or its subsidiaries.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2022
Stock-Based Compensation
Stock Based Compensation	7. Stock-Based Compensation 2019 Stock Plan On April 29, 2019, the Aemetis 2019 Stock Plan (the “2019 Stock Plan”) was approved by stockholders of the Company. This plan permits the grant of Incentive Stock Options, Non-Statutory Stock Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units, Performance Units, Performance Shares and other stock or cash awards as the Administrator may determine in its discretion. The 2019 Stock Plan’s term is 10 years and supersedes all prior plans. The 2019 Stock Plan authorized the issuance of 200,000 shares of common stock for the 2019 calendar year, in addition to permitting transferring and granting any available and unissued or expired options under the Amended and Restated 2007 Stock Plan in an amount up to 177,246 shares of common stock. With the approval of the 2019 Stock Plan, the Zymetis 2006 Stock Plan, and Amended and Restated 2007 Stock Plan (collectively, the “Stock Plans”) are terminated for granting any options under either plan. However, any options granted before the 2019 Stock Plan approved will remain outstanding and can be exercised, and any expired options will be available to grant under the 2019 Stock Plan. During the year ended December 31, 2021, 120,000 restricted stock awards and 1,140,000 stock option grants were issued and approved by the Company’s board of directors (“Board”) for employees and directors under the 2019 Stock Plan with 10-year terms and vesting terms ranging from immediately to 3 years. In January 2022, the company issued 932,800 incentive stock option for employees under the 2019 Stock Plan. In addition, 60,300 restricted stock award grants, with a fair value on date of grant of $11.31 per award, were issued to the Board. Common Stock Reserved for Issuance The following is a summary of awards granted under the Stock Plans: Shares Available for Grant Number of Shares Outstanding Weighted-Average Exercise Price Balance as of December 31, 2021 142 3,763 $ 2.29 Authorized 1,338 - - Options Granted (939 ) 939 11.31 RSAs Granted (60 ) - - Exercised - (266 ) 0.91 Forfeited/expired 43 (43 ) 11.55 Balance as of June 30, 2022 524 4,393 $ 4.21 As of June 30, 2022, there were 2.6 million options vested under the Stock Plans. Stock-based compensation for employees Stock-based compensation is accounted for in accordance with the provisions of ASC 718 Compensation-Stock Compensation Valuation and Expense Information All issuances of stock options or other issuances of equity instruments to employees as the consideration for services received by us are accounted for based on the fair value of the equity instrument issued. The fair value of options granted to employees is estimated on the grant date using the Black-Scholes option valuation model. This valuation model for stock based compensation expense requires us to make assumptions and judgments about the variables used in the calculation, including the fair value of our common stock, the expected term (the period of time that the options granted are expected to be outstanding), the volatility of our common stock, a risk-free interest rate, and expected dividends. Under ASU 2016-09 Improvements to Employee Share-Based Payments Accounting During the three months ended June 30, 2022 and 2021, the company granted 0 and 30,000 options, respectively. The weighted average fair value calculations for the options granted during these periods are based on the following assumptions: For the three months ended June 30, Description 2022 2021 Dividend-yield - % 0 % Risk-free interest rate - % 1.30 % Expected volatility - % 122.81 % Expected life (years) - 7 Market value per share on grant date $ - $ 13.09 Fair value per option on grant date $ - $ 11.79 As of June 30, 2022, the Company had $10.4 million of total unrecognized compensation expense for employees, which the Company will amortize over the 2.4 years of weighted average remaining term.

Outstanding Warrants

Outstanding Warrants	6 Months Ended
	Jun. 30, 2022
Outstanding Warrants
Outstanding Warrants	8. Outstanding Warrants The weighted average fair value calculations for warrants granted are based on the following weighted average assumptions: For the six months ended June 30, Description 2022 2021 Dividend-yield 0 % 0 % Risk-free interest rate 1.45 % 0.12 % Expected volatility 139.55 % 150.17 % Expected life (years) 4 2.00 Exercise price per warrant $ 13.33 $ 0.01 Market value per share on grant date $ 13.06 $ 2.49 Fair value per warrant on grant date $ 11.01 $ 2.48 A summary of historical warrant activity follows: Warrants Outstanding & Exercisable Weighted - Average Exercise Price Average Remaining Term in Years Outstanding December 31, 2020 95 $ 2.59 4.95 Granted 292 0.01 Exercised (332 ) 0.32 Outstanding December 31, 2021 55 $ 2.59 3.95 Granted 413 13.33 Exercised (113 ) 0.01 Outstanding June 30, 2022 355 $ 15.92 7.99 All of the above outstanding warrants are vested and exercisable as of June 30, 2022. As of June 30, 2022 and 2021, the Company had no unrecognized compensation expense related to warrants, respectively.

Agreements

Agreements	6 Months Ended
	Jun. 30, 2022
Agreements
Agreements	9. Agreements Working Capital Arrangement. As of June 30, 2022 and December 31, 2021, Aemetis had prepayments to J.D. Heiskell of $1.7 million and $4.0 million, respectively. The J.D. Heiskell sales and purchases activity associated with the J.D. Heiskell Purchase Agreement and J.D. Heiskell Procurement Agreement during the three and six months ended June 30, 2022 and 2021 were as follows: As of and for the three months ended June 30, As of and for the six months ended June 30, 2022 2021 2022 2021 Wet distiller's grains sales $ 15,150 $ 10,630 26,666 21,665 Corn oil sales 2,812 1,695 5,150 2,737 Corn purchases 54,352 42,166 98,362 80,159 Accounts receivable 232 65 232 65 Accounts payable 612 509 612 509 Ethanol and Wet Distillers Grains Marketing Arrangement. Accounts receivable associated with our marketing partners was $0.6 million and $1.2 million as of June 30, 2022 and December 31, 2021. For the three months ended June 31, 2022 and 2021, the Company expensed marketing costs of $0.8 million and $0.7 million, respectively, and for the six months ended June 30, 2022 and 2021, the Company expensed marketing costs of $1.5 million and $1.4 million, respectively, under the terms of both the Ethanol Marketing Agreement and the Wet Distillers Grains Marketing Agreement. These marketing costs are and are presented as a part of Selling, General, and Administration expense. As of June 30, 2022 and 2021, the Company has no forward sales commitments.

Segment Information

Segment Information	6 Months Ended
	Jun. 30, 2022
Segment Information
Segment Information	10. Segment Information Aemetis recognizes three reportable segments “California Ethanol”, “Dairy Renewable Natural Gas”, and “India Biodiesel.” The “California Ethanol” reportable segment includes the Company’s 65 million gallon per year Keyes Plant, and the adjacent land leased for the production of CO₂. The “Dairy Renewable Natural Gas” reportable segment includes, the dairy digesters, pipeline and gas condition hub for the production of biogas from dairies near Keyes, California. The “India Biodiesel” reportable segment includes the Company’s 50 million gallon per year nameplate capacity biodiesel manufacturing Kakinada Plant, the administrative offices in Hyderabad, India, and the holding companies in Nevada and Mauritius. The Company’s biodiesel is marketed and sold primarily to customers in India through brokers and by the Company directly. The Company has additional operating segments that were determined not to be reportable segments, including the Carbon Zero 1 facility in Riverbank, the Goodland Plant, and the research and development facility in Minnesota. Refer to the “All Other” category. Summarized financial information by reportable segment for the three months ended June 30, 2022 and 2021 follows: For the three months ended June 30, 2022 California Ethanol Dairy Renewable Natural Gas India Biodiesel All other Total Revenues from external customers $ 65,891 $ - $ 10 $ - $ 65,901 Intersegment revenues - 297 - - 297 Gross profit (loss) (152 ) (68 ) 10 (4 ) (214 ) Interest expense 4,869 7 - 1,792 6,668 Accretion and other expenses of Series A preferred units - 1,506 - - 1,506 Capital expenditures 5,366 6,696 69 928 13,059 Depreciation 977 154 164 30 1,325 Total Assets 66,580 55,731 9,324 46,817 178,452 For the three months ended June 30, 2021 California Ethanol Dairy Renewable Natural Gas India Biodiesel All other Total Revenues from external customers $ 54,730 $ - $ 154 $ - $ 54,884 Intersegment revenues - 694 - - 694 Gross profit (loss) 3,372 327 (15 ) (38 ) 3,646 Interest expense 4,986 3 - 230 5,219 Accretion and other expenses of Series A preferred units - 3,800 - - 3,800 Capital expenditures 767 2,503 1 3,104 6,375 Depreciation 1,050 142 174 12 1,378 Total Assets 76,452 27,814 12,306 26,715 143,287 A reconciliation of reportable segment revenues to total consolidated revenue for the three months ended June 30, 2022 and 2021 follow: 2022 2021 Total revenues for reportable segments $ 66,198 $ 55,578 Elmination of intersegment revenues (297 ) (694 ) Total consolidated revenues $ 65,901 $ 54,884 Summarized financial information by reportable segment for the six months ended June 30, 2022 and 2021 follows: For the six months ended June 30, 2022 California Ethanol Dairy Renewable Natural Gas India Biodiesel All other Total Revenues from external customers $ 117,932 $ - $ 18 $ - $ 117,950 Intersegment revenues - 632 - - 632 Gross profit (loss) (3,032 ) (275 ) 18 (10 ) (3,299 ) Interest expense 10,514 11 - 2,404 12,929 Accretion and other expenses of Series A preferred units - 3,146 - - 3,146 Capital expenditures 7,169 12,145 136 3,068 22,518 Depreciation 1,988 300 332 41 2,661 Total Assets 66,580 55,731 9,324 46,817 178,452 For the six months ended June 30, 2021 California Ethanol Dairy Renewable Natural Gas India Biodiesel All other Total Revenues from external customers $ 97,058 $ - $ 633 $ - $ 97,691 Intersegment revenues - 735 - - 735 Gross profit (loss) 241 (85 ) (70 ) (48 ) 38 Interest expense 10,685 6 - 1,708 12,399 Accretion and other expenses of Series A preferred units - 5,743 - - 5,743 Capital expenditures 775 6,895 118 5,147 12,935 Depreciation 2,102 284 358 20 2,764 Total Assets 76,452 27,814 12,306 26,715 143,287 A reconciliation of reportable segment revenues to total consolidated revenues for the six months ended June 30, 2022 and 2021 follow: 2022 2021 Total revenues for reportable segments $ 118,582 $ 98,426 Elmination of intersegment revenues (632 ) (735 ) Total consolidated revenues $ 117,950 $ 97,691 California Ethanol: Dairy Renewable Natural Gas:

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2022
Related Party Transactions
Related Party Transactions	11. Related Party Transactions The Company owes Eric McAfee, the Company’s Chairman and CEO, and McAfee Capital LLC (“McAfee Capital”), owned by Eric McAfee, $0.4 million in connection with employment agreements and expense reimbursements previously accrued as salaries expense and accrued liabilities. The Company previously prepaid $0.2 million to Redwood Capital, a company controlled by Eric McAfee, for the Company’s use of flight time on a corporate jet. As of June 30, 2022, $0.1 million remained as a prepaid expense. On November 4, 2021, the Audit Committee of the Company approved a guarantee fee of $0.4 million to Mr. McAfee. The balance of $0.1 million and $0.3 million, for guaranty fees, remained as an accrued liability as of June 30, 2022 and December 31, 2021, respectively. On January 12, 2022, the Audit Committee of the Company approved a one-time guarantee fee of $2.0 million to McAfee Capital in connection with McAfee Capital’s extension of certain guarantees of the Company’s indebtedness with Third Eye Capital. The Company paid this fee by issuing 180,000 shares of common stock of the Company. The Company owes various members of the Board amounts totaling $0.2 million as of June 30, 2022 and December 31, 2021, for each period, in connection with board compensation fees, which are included in accounts payable on the balance sheet. For the three months ended June 30, 2022 and 2021, the Company expensed $0.1 million respectively, in connection with board compensation fees. For the six months ended June 30, 2022 and 2021, the Company expensed $0.2 million during each period, in connection with board compensation fees.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2022
Subsequent Events
Subsequent Events	12. Subsequent Events Subordinated Debt Refinancing On July 1, 2022, the Subordinated Notes with two accredited investors were amended to extend the maturity date until the earlier of (i) December 31, 2022; (ii) completion of an equity financing by AAFK or Aemetis in an amount of not less than $25.0 million; or (iii) after the occurrence of an Event of Default (as defined in the Note and Warrant Purchase Agreements), including failure to pay interest or principal when due and breaches of note covenants. A 10% cash extension fee was paid in connection with the amendment by adding the fee to the balance of the new note and warrants to purchase 113 thousand shares of common stock were granted with a term of two years and an exercise price of $0.01 per share. Accounting for the July 1, 2022 amendments and the refinancing terms of the Subordinated Notes will be evaluated in accordance with ASC 470-50 Debt–- Modification and Extinguishment Third Eye Capital Limited Waiver and Amendment No. 24 On August 8th, 2022, Third Eye Capital agreed to Limited Waiver and Amendment No. 24 to the Note Purchase Agreement ("Amendment No. 24") to: (i) provide that the maturity date of the Third Eye Capital Notes may be further extended at our election to April 1, 2024 in exchange for an extension fee equal to 1% of the Note Indebtedness in respect to each Note, provided that such fee may be added to the outstanding principal balance of each Note on the effective date of each such extension, and (ii) provide for a waiver for certain covenant defaults. As consideration for such amendment and waivers, the borrowers also agreed to pay Third Eye Capital an amendment and waiver fee of $0.3 million in cash (the "Amendment No. 24 Fee"). Waiver and Amendment to Series A Preferred Unit Purchase Agreement On August 8th, 2022, ABGL, Protair-X America, Inc. (“Protair”), and Third Eye Capital entered into a Waiver and Amendment to Series A Preferred Unit Purchase Agreement (“PUPA Amendment") which amends that certain Series A Preferred Unit Purchase Agreement (“PUPA”) dated as of December 20, 2018. The PUPA Amendment provides for: (i) a waiver of certain covenants prohibiting the internal reorganization of ABGL subsidiaries and the incurrence of indebtedness by ABGL and its subsidiaries pursuant to a USDA loan, provided that, among other things, Third Eye Capital shall have received a repayment of at least $[7.3] million to be applied to the Carbon Revolving Line contemporaneously with the closing of the USDA loan; (ii) a waiver of certain operational defaults under the PUPA; and (iii) an amendment which (a) requires ABGL to redeem all of the outstanding Series A Preferred Units by December 31, 2022 (the “Final Redemption Date”) for $116 million; and (b) provides ABGL the right to redeem all of the outstanding Series A Preferred Units by September 30, 2022 for $106 million. The PUPA Amendment further provides that the failure to redeem the Series A Preferred Units by the Final Redemption Date would constitute a triggering event requiring ABGL to enter into a credit agreement with Protair and Third Eye Capital in substantially the form attached to the PUPA Amendment.

Management's Plan

Management's Plan	6 Months Ended
	Jun. 30, 2022
Management's Plan
Management's Plan	13. Management’s Plan The accompanying financial statements have been prepared contemplating the realization of assets and satisfaction of liabilities in the normal course of business. As a result of negative capital and negative operating results, and collateralization of substantially all of the company assets, the Company has been reliant on its senior secured lender to provide additional funding and has been required to remit substantially all excess cash from operations to the senior secured lender. In order to meet its obligations during the next twelve months, the Company will need to either refinance the Company’s debt or receive the continued cooperation of its senior lender. This dependence on the senior lender raises substantial doubt about the Company’s ability to continue as a going concern. The Company plans to pursue the following strategies to improve the course of the business. For the Keyes Plant, we plan to operate the plant and continue to improve financial performance by adopting new technologies or process changes that allow for energy efficiency, cost reduction or revenue enhancements, execute upon awarded grants that improve energy and operational efficiencies resulting in lower cost, lower carbon demands and overall margin improvement. For the ABGL project, we plan to operate the biogas digesters to capture and monetize biogas as well as continue to build new dairy digesters and extend the existing pipeline in order to capture the higher carbon credits available in California. Funding for continued construction is based upon obtaining government guaranteed loans and executing on existing and new state grant programs. For the Riverbank project, we plan to raise the funds necessary to construct and operate the Carbon Zero 1 plant using loan guarantees and public financings based upon the licensed technology that generate federal and state carbon credits available for ultra-low carbon fuels utilizing lower cost, non-food advanced feedstocks to significantly increase margins. For the Kakinada Plant, we plan to develop sales channels for domestic products as the costs of feedstock normalize against the price of diesel, as recently announced governmental incentives take effect to promote the blending of biodiesel, and as feedstocks such as refined animal tallow are used domestically and exported. Additionally, we are in the process of obtaining approval to export refined animal tallow and biodiesel produced using animal tallow into international markets as the use of refined animal tallow received approval from the Pollution Control Board of India for production of biodiesel. In addition to the above we plan to continue to locate funding for existing and new business opportunities through a combination of working with our senior lender, restructuring existing loan agreements, selling bonds in the taxable and tax-exempt markets, selling equity through the ATM and otherwise, selling the current EB-5 Phase II offering, or by vendor financing arrangements.

Nature of Activities and Summ_2

Nature of Activities and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Nature of Activities and Summary of Significant Accounting Policies
Nature Of Activities	Nature of Activities. Founded in 2006 and headquartered in Cupertino, California, Aemetis, Inc. (collectively with its subsidiaries on a consolidated basis, “Aemetis,” the “Company,” “we,” “our” or “us”) is an international renewable natural gas and renewable fuels company focused on the acquisition, development and commercialization of innovative technologies that replace traditional petroleum-based products. We own and operate a 65 million gallon per year ethanol production facility located in Keyes, California (the “Keyes Plant”). In addition to low carbon renewable fuel ethanol, the Keyes Plant produces Wet Distillers Grains (“WDG”), Distillers Corn Oil (“DCO”), and Condensed Distillers Solubles (“CDS”), all of which are sold as animal feed to local dairies and feedlots. In the fourth quarter of 2021, an ethanol zeolite membrane dehydration system was installed at the Keyes Plant and is in the process of being commissioned, a key first step in the electrification of the Keyes Plant. During 2018, Aemetis Biogas, LLC (“ABGL”) was formed to construct bio-methane anaerobic digesters at local dairies near the Keyes Plant, many of whom also purchase WDG produced at the Keyes Plant. The digesters are connected via an underground private pipeline owned by ABGL to a gas cleanup and compression unit being built at the Keyes Plant to produce dairy renewable natural gas (“RNG”). Upon receiving the bio-methane from the dairies, impurities are removed, and the bio-methane is converted to negative carbon intensity RNG that will either be injected into the statewide PG&E gas utility pipeline, supplied as compressed RNG that will service local trucking fleets, or used as renewable process energy at the Keyes Plant. Our Dairy Renewable Natural Gas segment, comprised of ABGL, has completed Phase 1 of our California biogas digester network and pipeline system that converts waste dairy methane gas into RNG, including two operational dairies and seven miles of pipeline. ABGL is now executing Phase 2 construction with the completion of sixteen miles of pipeline and the commissioning of the biogas-to-RNG upgrade unit at the Keyes Plant as well as beginning construction of additional dairy digesters. During the second quarter of 2022, Aemetis has completed construction of a third dairy digester and commissioning of the centralized gas cleanup facility and utility gas interconnect located at the Keyes Plant where dairy biogas will be upgraded to RNG and injected into the utility pipeline. Upon receiving pathway certification from the California Air Resources Board (CARB), the fuel is expected to be delivered into the Northern California gas delivery system. Our ‘Carbon Zero’ biofuels production plants are designed to produce biofuels, including sustainable aviation fuel (“SAF”) and diesel fuel utilizing renewable hydrogen and non-edible renewable oils sourced from existing Aemetis biofuels plants and other sources. The first plant to be built, in Riverbank, California, “Carbon Zero 1”, is expected to utilize hydroelectric and other renewable power available onsite to produce 90 million gallons per year of SAF, renewable diesel, and other byproducts. The plant is expected to supply the aviation and truck markets with ultra-low carbon renewable fuels to reduce GHG emissions and other pollutants associated with conventional petroleum-based fuels. By producing ultra-low carbon renewable fuels, the Company expects to capture higher value D3 Renewable Identification Numbers (“RINs”) and California’s LCFS credits. D3 RINs have a higher value in the marketplace than D6 RINs due to D3 RINs’ relative scarcity and mandated pricing formula from the United States Environmental Protection Agency (“EPA”). On April 1, 2021, we established Aemetis Carbon Capture, Inc. to build Carbon Capture and Sequestration (CCS) projects to generate LCFS and IRS 45Q credits by injecting CO₂ into wells which are monitored for emissions to ensure the long-term sequestration of carbon underground. The CCS projects are expected to capture and sequester up to two million metric tons per year of CO₂ at the two Aemetis biofuels plant sites in Keyes and Riverbank, California. In July 2022, Aemetis purchased 24 acres, on the Riverbank Industrial Complex site in Riverbank, California, to develop a CCS injection well. The Company plans to construct a characterization well to obtain both the data and well design information required for the EPA Class VI CO₂ injection well permit application. The well is expected to sequester up to one million metric tons per year of CO₂. We also own and operate a production facility on the East Coast of India (the “Kakinada Plant”) with a nameplate capacity of 150 thousand metric tons per year, or about 50 million gallons per year, producing high quality distilled biodiesel and refined glycerin for customers in India and Europe. The Kakinada Plant is capable of processing a variety of vegetable oils and animal fat waste feedstocks into biodiesel that meet international product standards. The Kakinada Plant also distills the crude glycerin byproduct from the biodiesel refining process into refined glycerin, which is sold to the pharmaceutical, personal care, paint, adhesive and other industries.
Basis Of Presentation And Consolidation	Basis of Presentation and Consolidation. All intercompany balances and transactions have been eliminated in consolidation. The accompanying consolidated condensed balance sheet as of June 30, 2022, the consolidated condensed statements of operations and comprehensive income (loss) for the three and six months ended June 30, 2022 and 2021, the consolidated condensed statements of cash flows for the six months ended June 30, 2022 and 2021, and the consolidated condensed statements of stockholders’ deficit for the three and six months ended June 30, 2022 and 2021 are unaudited. The consolidated condensed balance sheet as of December 31, 2021 was derived from the 2021 audited consolidated financial statements and notes thereto. The consolidated condensed financial statements in this report should be read in conjunction with the 2021 audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2021. The accompanying consolidated condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. In the opinion of Company’s management, the unaudited interim consolidated condensed financial statements as of and for the three and six months ended June 30, 2022 and 2021 have been prepared on the same basis as the audited consolidated statements as of and for the year ended December 31, 2021 and reflect all adjustments, consisting primarily of normal recurring adjustments, necessary for the fair presentation of its statement of financial position, results of operations and cash flows. The results of operations for the three and six months ended June 30, 2022 are not necessarily indicative of the operating results for any subsequent quarter, for the full fiscal year or any future periods.
Use Of Estimates	Use of Estimates
Revenue Recognition	Revenue Recognition California Ethanol: The below table shows our sales in our California Ethanol segment by product category: For the three months ended June 30, For the six months ended June 30, 2022 2021 2022 2021 Ethanol and high-grade alcohol sales $ 47,656 $ 42,169 $ 85,551 $ 72,089 Wet distiller's grains sales 15,150 10,630 26,666 21,665 Other sales 3,085 1,931 5,715 3,304 $ 65,891 $ 54,730 $ 117,932 $ 97,058 We have elected to adopt the practical expedient that allows for ignoring the significant financing component of a contract when estimating the transaction price when the transfer of promised goods to the customer and customer payment for such goods are expected to be within one year of contract inception. Further, we have elected to adopt the practical expedient in which incremental costs of obtaining a contract are expensed when the amortization period would otherwise be less than one year. We also assessed principal versus agent criteria as we buy our feedstock from our customers and process and sell finished goods to those customers in certain contractual agreements. For our California Ethanol segment, we buy corn as feedstock for the production of ethanol, from our working capital partner J.D. Heiskell. Prior to May 13, 2020, we sold all our ethanol, WDG, and corn oil to J.D. Heiskell and we bought all our corn to process into ethanol from J.D. Heiskell. After May 13, 2020, we sold most of our fuel ethanol to one customer, Kinergy, and sold all WDG and corn oil to J.D. Heiskell. During the second quarter of 2021, we signed a biofuels offtake agreement with Murex, and beginning on October 1, 2021 we sold all our fuel ethanol to Murex. We only have customer relationships with Kinergy and Murex, hence the principal and agent criteria are not applied. However, we are still buying corn and selling WDG and corn oil to J.D.Heiskell. We analyzed the principal versus agent relationship criteria below. We consider the purchase of corn as a cost of goods sold and the sale of WDG and, corn oil, upon trucks leaving the Keyes Plant, as revenue on the basis that (i) we control and bear the risk of gain or loss on the processing of corn which is purchased at market prices into ethanol and (ii) we have legal title to the goods during the processing time. The pricing for both WDG and corn oil is set independently. Revenues from WDG and corn oil are billed net of the related transportation and marketing charges. The transportation component is accounted for in cost of goods sold and the marketing component is accounted for in sales, general and administrative expense. Transportation and marketing charges are known within days of the transaction and are recorded at the actual amounts. We have elected an accounting policy under which these charges have been treated as fulfillment activities provided after control has transferred. As a result, these charges are recognized in cost of goods sold and selling, general and administrative expenses, respectively, when revenue is recognized. Revenues are recorded at the gross invoiced amount. Hence, we are the principal in California Ethanol segment where our customer and vendor may be the same. Dairy Renewable Natural Gas: India Biodiesel: The below table shows our sales in our India Biodiesel Segment by product category: For the three months ended June 30, For the six months ended June 30, 2022 2021 2022 2021 Biodiesel sales $ - $ 107 $ - $ 465 Refined glycerin sales - 9 - 125 Other sales 10 38 18 43 $ 10 $ 154 $ 18 $ 633 In India, we also assessed principal versus agent criteria as we buy our feedstock from our customers and process and sell finished goods to those same customers in certain contractual agreements. In those cases, we receive the legal title to feedstock from our customers once it is on our premises. We control the processing and production of biodiesel based on contract terms and specifications. The pricing for both feedstock and biodiesel is set independently. We hold the title and risk to biodiesel according to agreements when we enter into in these situations. Hence, we are the principal in India sales scenarios where our customer and vendor may be the same.
Cost Of Goods Sold	Cost of Goods Sold
Shipping And Handling Costs	Shipping and Handling Costs.
Research And Development	Research and Development.
Cash And Cash Equivalents	Cash and Cash Equivalents.
Accounts Receivable	Accounts Receivable. The Company maintains an allowance for doubtful accounts for balances that appear to have specific collection issues. The collection process is based on the age of the invoice and requires attempted contacts with the customer at specified intervals. If, after a specified number of days, the Company has been unsuccessful in its collection efforts, a bad debt allowance is recorded for the balance in question. Delinquent accounts receivables are charged against the allowance for doubtful accounts once un-collectability has been determined. The factors considered in reaching this determination are the apparent financial condition of the customer and the Company’s success in contacting and negotiating with the customer. If the financial condition of the Company’s customers were to deteriorate, additional allowances may be required. We reserved $1.4 million in the allowances for doubtful accounts as of December 31, 2021 and wrote off the balances as uncollectible during the second quarter of 2022.
Inventories	Inventories
Variable Interest Entities	Variable Interest Entities.
Property, Plant And Equipment	Property, Plant and Equipment The Company evaluates the recoverability of long-lived assets with finite lives in accordance with ASC Subtopic 360-10-35 Property Plant and Equipment—Subsequent Measurements,
California Energy Commission Low-carbon Fuel Production Program	California Energy Commission Low-Carbon Fuel Production Program
California Department Of Food And Agriculture Dairy Digester Research And Development Grant	California Department of Food and Agriculture Dairy Digester Research and Development Grant In October 2020, the Company was awarded $7.8 million in matching grants from the CDFA Dairy Digester Research and Development program. The CDFA grant reimburses the Company for costs required to permit and construct six of the Company’s biogas capture systems under contract with central California dairies. The Company has received $1.6 million from the CDFA 2020 grant program as of June 30, 2022, as reimbursement for actual costs incurred. Due to the uncertainty associated with the approval process under the grant program, the Company recognized the grant as a reduction of costs in the period when payment is received.
California Energy Commission Low Carbon Advanced Ethanol Grant Program	California Energy Commission Low Carbon Advanced Ethanol Grant Program.
U.s. Department Of Food And Agriculture Forest Service Grant	U.S. Department of Food and Agriculture Forest Service Grant.
California Energy Commission Grant For Solar Microgrid, Dsc And Battery Backup System	California Energy Commission Grant for Solar Microgrid, DSC and Battery Backup System.
California Department of Forestry and Fire Protection Grant	California Department of Forestry and Fire Protection Grant.
California Department of Forestry and Fire Protection Grant 2	California Department of Forestry and Fire Protection Grant.
U.S Forest Service Community Wood Grant	U.S Forest Service Community Wood Grant.
USDA's Biofuel Producer Program Grant	USDA’s Biofuel Producer Program Grant.
Basic And Diluted Net Loss Per Share	Basic and Diluted Net Loss per Share. The following table shows the number of potentially dilutive shares excluded from the diluted net loss per share calculation as of June 30, 2022 and 2021: As of June 30, 2022 June 30, 2021 Series B preferred (post split basis) 127 132 Common stock options and warrants 4,748 4,252 Debt with conversion feature at $30 per share of common stock 1,228 1,273 Total number of potentially dilutive shares excluded from the diluted net (loss) per share calculation 6,103 5,657
Comprehensive Income (loss)	Comprehensive Income (Loss). Comprehensive Income (Loss)
Foreign Currency Translation/transactions	Foreign Currency Translation/Transactions.
Segments	Segments. The “California Ethanol” reportable segment includes the Company’s 65 million gallon per year Keyes plant and the adjacent land leased for the production of CO₂. The “Dairy Renewable Natural Gas” reportable segment include, the dairy digesters, pipeline and gas condition hub for the production of biogas from dairies near Keyes, California. The “India Biodiesel” reportable segment includes the Company’s 50 million gallon per year nameplate capacity biodiesel manufacturing Kakinada Plant, the administrative offices in Hyderabad, India, and the holding companies in Nevada and Mauritius. The Company’s biodiesel is marketed and sold primarily to customers in India through brokers and by the Company directly. The Company has additional operating segments that were determined not to be reportable segments, including the Carbon Zero 1 facility in Riverbank, the Goodland Plant in Kansas and the research and development facility in Minnesota. Refer to the “All Other” category.
Fair Value Of Financial Instruments	Fair Value of Financial Instruments.
Commitments And Contingencies	Commitments and Contingencies. Contingencies
Convertible Instruments	Convertible Instruments
Debt Modification Accounting	Debt Modification Accounting Debt–Modification and Extinguishments For a complete summary of the Company’s significant accounting policies, please refer to the Company’s audited financial statements and notes thereto for the years ended December 31, 2021 and 2020 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 10, 2022.

Nature of Activities and Summ_3

Nature of Activities and Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2022
Nature of Activities and Summary of Significant Accounting Policies
Schedule Of America By Product Category	For the three months ended June 30, For the six months ended June 30, 2022 2021 2022 2021 Ethanol and high-grade alcohol sales $ 47,656 $ 42,169 $ 85,551 $ 72,089 Wet distiller's grains sales 15,150 10,630 26,666 21,665 Other sales 3,085 1,931 5,715 3,304 $ 65,891 $ 54,730 $ 117,932 $ 97,058 For the three months ended June 30, For the six months ended June 30, 2022 2021 2022 2021 Biodiesel sales $ - $ 107 $ - $ 465 Refined glycerin sales - 9 - 125 Other sales 10 38 18 43 $ 10 $ 154 $ 18 $ 633
Schedule Of Dilutive Securities	As of June 30, 2022 June 30, 2021 Series B preferred (post split basis) 127 132 Common stock options and warrants 4,748 4,252 Debt with conversion feature at $30 per share of common stock 1,228 1,273 Total number of potentially dilutive shares excluded from the diluted net (loss) per share calculation 6,103 5,657

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2022
Inventories
Schedule Of Inventories	As of June 30, 2022 December 31, 2021 Raw materials $ 903 $ 727 Work-in-progress 2,522 2,083 Finished goods 1,480 2,316 Total inventories $ 4,905 $ 5,126

Property Plant and Equipment (T

Property Plant and Equipment (Tables)	6 Months Ended
	Jun. 30, 2022
Property Plant and Equipment
Schedule Of Property, Plant And Equipment	As of June 30, 2022 December 31, 2021 Land $ 6,156 $ 4,082 Plant and buildings 122,165 97,110 Furniture and fixtures 1,504 1,334 Machinery and equipment 5,203 5,294 Tenant improvements 56 - Construction in progress 51,279 55,859 Property held for development 15,437 15,437 Finance lease right of use assets 3,152 2,317 Total gross property, plant & equipment 204,952 181,433 Less accumulated depreciation (48,162 ) (46,332 ) Total net property, plant & equipment $ 156,790 $ 135,101
Depreciation Of Property, Plant, And Equipment	Years Plant and buildings 20 - 30 Machinery and equipment 5 - 15 Furniture and fixtures 3 - 5

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2022
Debt
Schedule Of Debt	June 30, 2022 December 31, 2021 Third Eye Capital term notes $ 7,089 $ 7,095 Third Eye Capital revolving credit facility 54,039 75,980 Third Eye Capital revenue participation term notes 11,912 11,915 Third Eye Capital acquisition term notes 26,464 26,461 Third Eye Capital Fuels Revolving Line 18,393 - Third Eye Capital Carbon Revolving Line 22,187 - Cilion shareholder seller notes payable 6,718 6,619 Subordinated notes 15,105 14,304 EB-5 promissory notes 41,004 40,692 Term loans on capital expenditures 5,697 5,701 Total debt 208,608 188,767 Less current portion of debt 24,859 22,778 Total long term debt $ 183,749 $ 165,989
Maturities Of Long-term Debt	Twelve Months ended June 30, Debt Repayments 2023 $ 24,859 2024 132,218 2025 26,191 2026 29,473 2027 944 There after 1,169 Total debt 214,854 Debt issuance costs (6,246 ) Total debt, net of debt issuance costs $ 208,608

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies
Schedule Of Lease Expense And Sublease Income	Three Months ended June 30, Six Months ended June 30, 2022 2021 2022 2021 Operating lease cost Operating lease expense $ 159 $ 204 $ 347 $ 408 Short term lease expense 75 71 102 110 Variable lease expense 23 21 46 54 Total operating lease cost $ 257 $ 296 $ 495 $ 572 Finance lease cost Amortization of right-of-use assets $ 28 $ 55 $ 89 $ 110 Interest on lease liabilities 99 20 119 41 Total finance lease cost $ 127 $ 75 $ 208 $ 151
Cash Paid For Amounts Included In The Measurement Of Lease Liabilities	Three Months ended June 30, Six Months ended June 30, 2022 2021 2022 2021 Operating cash flows used in operating leases $ 174 $ 173 $ 338 $ 340 Operating cash flows used in finance leases 99 20 118 41 Financing cash flows used in finance leases 50 124 $ 182 248
Supplemental Non-cash Flow Information Related To Right-of-use Asset And Lease Liabilities	Three Months ended June 30, Six Months ended June 30, 2022 2021 2022 2021 Operating leases Accretion of the lease liability $ 85 $ 96 $ 179 $ 195 Amortization of right-of-use assets 74 108 168 213 Weighted Average Remaining Lease Term Operating leases 5.9 years Finance leases 14.1 years Weighted Average Discount Rate Operating leases 14.0 % Finance leases 13.4 %
Supplemental Balance Sheet Information	June 30, 2022 December 31, 2021 Operating leases Operating lease right-of-use assets $ 2,294 $ 2,462 Current portion of operating lease liability 258 260 Long term operating lease liability 2,191 2,318 Total operating lease liabilities 2,449 2,578 Finance leases Property and equipment, at cost $ 3,152 $ 2,317 Accumulated depreciation (72 ) (376 ) Property and equipment, net 3,080 1,941 Other current liability 196 550 Other long term liabilities 2,849 720 Total finance lease liabilities 3,045 1,270
Maturities Of Operating And Finance Lease Liabilities	Twelve months ended June 30, Operating leases Finance leases 2023 $ 572 $ 561 2024 581 279 2025 599 179 2026 617 151 2027 636 145 There after 606 11,000 Total lease payments 3,611 12,315 Less imputed interest (1,162 ) (9,270 ) Total lease liability $ 2,449 $ 3,045
Schedule of components of lease income	June 30, 2022 June 30, 2021 Lease income $ 377 $ -
Summary of future lease commitments	Twelve months ended June 30, 2023 $ 830 2024 686 2025 541 2026 474 2027 474 There after 1,303 Total future lease commitments $ 4,308

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2022
Stock-Based Compensation
Schedule Of Options Granted Under Employee Stock Plans	Shares Available for Grant Number of Shares Outstanding Weighted-Average Exercise Price Balance as of December 31, 2021 142 3,763 $ 2.29 Authorized 1,338 - - Options Granted (939 ) 939 11.31 RSAs Granted (60 ) - - Exercised - (266 ) 0.91 Forfeited/expired 43 (43 ) 11.55 Balance as of June 30, 2022 524 4,393 $ 4.21
Schedule Of Weighted Average Fair Value Calculations For Options	For the three months ended June 30, Description 2022 2021 Dividend-yield - % 0 % Risk-free interest rate - % 1.30 % Expected volatility - % 122.81 % Expected life (years) - 7 Market value per share on grant date $ - $ 13.09 Fair value per option on grant date $ - $ 11.79

Outstanding Warrants (Tables)

Outstanding Warrants (Tables)	6 Months Ended
	Jun. 30, 2022
Outstanding Warrants
Weighted Average Assumptions	For the six months ended June 30, Description 2022 2021 Dividend-yield 0 % 0 % Risk-free interest rate 1.45 % 0.12 % Expected volatility 139.55 % 150.17 % Expected life (years) 4 2.00 Exercise price per warrant $ 13.33 $ 0.01 Market value per share on grant date $ 13.06 $ 2.49 Fair value per warrant on grant date $ 11.01 $ 2.48
Schedule Of Warrant Activity	Warrants Outstanding & Exercisable Weighted - Average Exercise Price Average Remaining Term in Years Outstanding December 31, 2020 95 $ 2.59 4.95 Granted 292 0.01 Exercised (332 ) 0.32 Outstanding December 31, 2021 55 $ 2.59 3.95 Granted 413 13.33 Exercised (113 ) 0.01 Outstanding June 30, 2022 355 $ 15.92 7.99

Agreements (Tables)

Agreements (Tables)	6 Months Ended
	Jun. 30, 2022
Agreements
Schedule Of Working Capital Agreement Activity	As of and for the three months ended June 30, As of and for the six months ended June 30, 2022 2021 2022 2021 Wet distiller's grains sales $ 15,150 $ 10,630 26,666 21,665 Corn oil sales 2,812 1,695 5,150 2,737 Corn purchases 54,352 42,166 98,362 80,159 Accounts receivable 232 65 232 65 Accounts payable 612 509 612 509

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Jun. 30, 2022
Segment Information
Schedule Of Segment Information	For the three months ended June 30, 2022 California Ethanol Dairy Renewable Natural Gas India Biodiesel All other Total Revenues from external customers $ 65,891 $ - $ 10 $ - $ 65,901 Intersegment revenues - 297 - - 297 Gross profit (loss) (152 ) (68 ) 10 (4 ) (214 ) Interest expense 4,869 7 - 1,792 6,668 Accretion and other expenses of Series A preferred units - 1,506 - - 1,506 Capital expenditures 5,366 6,696 69 928 13,059 Depreciation 977 154 164 30 1,325 Total Assets 66,580 55,731 9,324 46,817 178,452 For the three months ended June 30, 2021 California Ethanol Dairy Renewable Natural Gas India Biodiesel All other Total Revenues from external customers $ 54,730 $ - $ 154 $ - $ 54,884 Intersegment revenues - 694 - - 694 Gross profit (loss) 3,372 327 (15 ) (38 ) 3,646 Interest expense 4,986 3 - 230 5,219 Accretion and other expenses of Series A preferred units - 3,800 - - 3,800 Capital expenditures 767 2,503 1 3,104 6,375 Depreciation 1,050 142 174 12 1,378 Total Assets 76,452 27,814 12,306 26,715 143,287 For the six months ended June 30, 2022 California Ethanol Dairy Renewable Natural Gas India Biodiesel All other Total Revenues from external customers $ 117,932 $ - $ 18 $ - $ 117,950 Intersegment revenues - 632 - - 632 Gross profit (loss) (3,032 ) (275 ) 18 (10 ) (3,299 ) Interest expense 10,514 11 - 2,404 12,929 Accretion and other expenses of Series A preferred units - 3,146 - - 3,146 Capital expenditures 7,169 12,145 136 3,068 22,518 Depreciation 1,988 300 332 41 2,661 Total Assets 66,580 55,731 9,324 46,817 178,452 For the six months ended June 30, 2021 California Ethanol Dairy Renewable Natural Gas India Biodiesel All other Total Revenues from external customers $ 97,058 $ - $ 633 $ - $ 97,691 Intersegment revenues - 735 - - 735 Gross profit (loss) 241 (85 ) (70 ) (48 ) 38 Interest expense 10,685 6 - 1,708 12,399 Accretion and other expenses of Series A preferred units - 5,743 - - 5,743 Capital expenditures 775 6,895 118 5,147 12,935 Depreciation 2,102 284 358 20 2,764 Total Assets 76,452 27,814 12,306 26,715 143,287
Schedule Of Reconciliation Of Reportable Segment	2022 2021 Total revenues for reportable segments $ 66,198 $ 55,578 Elmination of intersegment revenues (297 ) (694 ) Total consolidated revenues $ 65,901 $ 54,884 2022 2021 Total revenues for reportable segments $ 118,582 $ 98,426 Elmination of intersegment revenues (632 ) (735 ) Total consolidated revenues $ 117,950 $ 97,691

Nature of Activities and Summ_4

Nature of Activities and Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Sales	$ 65,901	$ 54,884	$ 117,950	$ 97,691
California [Member]
Sales	65,891	54,730	117,932	97,058
Ethanol and high-grade alcohol sales | California [Member]
Sales	47,656	42,169	85,551	72,089
Wet distiller's grains sales | California [Member]
Sales	15,150	10,630	26,666	21,665
Other Sales Member | California [Member]
Sales	$ 3,085	$ 1,931	$ 5,715	$ 3,304

Nature of Activities and Summ_5

Nature of Activities and Summary of Significant Accounting Policies (Details 1) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Sales	$ 65,901	$ 54,884	$ 117,950	$ 97,691
India Biodiesel
Sales	10	154	18	633
Other sales | India Biodiesel
Sales	10	38	18	43
Biodiesel sales | India Biodiesel
Sales	0	107	0	465
Refined Glycerin sales | India Biodiesel
Sales	$ 0	$ 9	$ 0	$ 125

Nature of Activities and Summ_6

Nature of Activities and Summary of Significant Accounting Policies (Details 2) - shares	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Total Number Of Potentially Dilutive Shares Excluded From The Basic And Diluted Net Loss Per Share Calculation (in Thousands)	6,103	5,657
Series B preferred (post split basis)
Total Number Of Potentially Dilutive Shares Excluded From The Basic And Diluted Net Loss Per Share Calculation (in Thousands)	127	132
Common stock options and warrants
Total Number Of Potentially Dilutive Shares Excluded From The Basic And Diluted Net Loss Per Share Calculation (in Thousands)	4,748	4,252
Debt with conversion feature at $30 per share of common stock
Total Number Of Potentially Dilutive Shares Excluded From The Basic And Diluted Net Loss Per Share Calculation (in Thousands)	1,228	1,273

Nature of Activities and Summ_7

Nature of Activities and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	1 Months Ended		6 Months Ended
	May 31, 2022	Oct. 31, 2020	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Awarded Grants			$ 8,000,000
Gallon Per Year			90,000,000
Contributions			1,550,000
Allowance For Doubtful Accounts Receivable					$ 3,300,000
Reimbursement For Actual Costs Incurred			6,147,000	$ 1,224,000
US DFAFSG [Member]
Awarded Grants			245,000
India
Gallon Per Year			50,000,000
Kakinada Plant One [Member]
Gallon Per Year			50,000,000
Nameplate Capacity			150,000
CEC-LCFPP [Member]
Awarded Grants			4,200,000
Reimbursement For Actual Costs Incurred			3,800,000
CDFA [Member]
Awarded Grants	$ 642,000	$ 7,800,000	3,200,000
Contributions			2,400,000
Reimbursement For Actual Costs Incurred		$ 1,600,000	14,200,000
CEC-LCAEGP [Member]
Awarded Grants	500,000		5,000,000
Gallon Per Year	2,000,000
Contributions	5,800,000		7,900,000
Actual Expenses			5,000,000
Capital Expenditures	$ 2,000,000		1,700,000
Accounts Receivable [Member]
Reimbursement For Actual Costs Incurred			$ 73,000

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Inventories
Raw Materials	$ 903	$ 727
Work-in-progress	2,522	2,083
Finished Goods	1,480	2,316
Total Inventories	$ 4,905	$ 5,126

Inventories (Details Narrative)

Inventories (Details Narrative) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Inventories
Lower Cost Of Market Impairment	$ 165,000	$ 0

Property, Plant and Equipment (

Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Property Plant and Equipment
Land	$ 6,156	$ 4,082
Plant And Buildings	122,165	97,110
Furniture And Fixtures	1,504	1,334
Machinery And Equipment	5,203	5,294
Tenant Improvements	56	0
Construction In Progress	51,279	55,859
Property Held For Development	15,437	15,437
Finance Lease Right Of Use Assets	3,152	2,317
Total Gross Property, Plant & Equipment	204,952	181,433
Less Accumulated Depreciation	(48,162)	(46,332)
Total Net Property, Plant & Equipment	$ 156,790	$ 135,101

Property, Plant and Equipment_2

Property, Plant and Equipment (Details 1)	6 Months Ended
	Jun. 30, 2022
Minimum [Member] | Machinery and Equipment [Member]
Depreciation (years)	5 years
Minimum [Member] | Furniture and Fixtures [Member]
Depreciation (years)	3 years
Minimum [Member] | Plant and Buildings [Member]
Depreciation (years)	20 years
Maximum [Member] | Machinery and Equipment [Member]
Depreciation (years)	15 years
Maximum [Member] | Furniture and Fixtures [Member]
Depreciation (years)	5 years
Maximum [Member] | Plant and Buildings [Member]
Depreciation (years)	30 years

Property, Plant and Equipment_3

Property, Plant and Equipment (Details Narrative) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Property Plant and Equipment
Interest Capitalized In Property	$ 2.6	$ 0.9	$ 4.7	$ 1.5
Depreciation Expense	$ 1.3	$ 1.4	$ 2.7	$ 2.8

Debt (Details)

Debt (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Total Debt	$ 208,608,000	$ 188,767,000
Less Current Portion Of Debt	24,859,000	22,778,000
Total Long Term Debt	183,749,000	165,989,000
Senior Debt-TEC | Promissory Notes [Member]
Total Debt	7,089,000	7,095,000
EB-5 Promissory Notes
Total Debt	41,004,000	40,692,000
Term Loan on Equipment Purchase
Total Debt	5,697,000	5,701,000
Subordinated Notes
Total Debt	15,105,000	14,304,000
Capital Carbon Revolving Line
Total Debt	22,187,000	0
Senior Debt | Promissory Notes [Member]
Total Debt	0
Senior Debt | Revenue Participation Term Notes
Total Debt	11,912,000	11,915,000
Capital Fuels Revolving Line | Senior Debt
Total Debt	18,393,000	0
Subordinated Debt [Member] | Cilion [Member]
Total Debt	6,718,000	6,619,000
Revolving Credit Facility | Senior Debt-TEC
Total Debt	54,039,000	75,980,000
Acquisition Term Notes | Senior Debt
Total Debt	$ 26,464,000	$ 26,461,000

Debt (Details 1)

Debt (Details 1) $ in Thousands	Jun. 30, 2022 USD ($)
Twelve Months ended June 30,
2023	$ 24,859
2024	132,218
2025	26,191
2026	29,473
2027	944
Thereafter	1,169
Total Debt	214,854
Debt Issuance Costs	(6,246)
Total Debt, Net Of Debt Issuance Costs	$ 208,608

Debt (Details Narrative)

Debt (Details Narrative) - USD ($)					3 Months Ended	6 Months Ended
	May 11, 2022	Aug. 09, 2021	Mar. 14, 2021	Mar. 06, 2020	Mar. 31, 2022	Jun. 30, 2022	Mar. 08, 2022	Mar. 02, 2022	Dec. 31, 2021	Nov. 05, 2021	Jun. 30, 2021	Feb. 27, 2019	Jul. 06, 2012
Warrants Exercisable						$ 13.33					$ 0.01
Net Of Debt Issuance						$ 208,608,000			$ 188,767,000
Net And The Related Liability						15,856,000			14,586,000
Other Long Term Debt						11,665,000			12,038,000
McAfee [Member]
Net Amount At Risk By Product And Guarantee, Net Amount At Risk						8,000,000
Revolving Credit Facility
Debt Instrument Face Amount						$ 5,520,000
Debt Instrument Interest Rate						18.50%
Revolving Credit Facility Accrues Interest Rate						13.75%
Unamortized Debt Issuance Cost						$ 1,100,000
New Credit Facility
Property Taxes						$ 6,100,000
Senior Debt | Acquisition Term Notes
Maturity Period						Apr. 01, 2023
Unamortized Debt Issuance Cost						$ 202,000
Revolving Credit Facility Accrues Interest Rate						10.75%
Principal Outstanding						$ 26,700,000
Redemption Fees						7,500,000
Debt Instrument Fair Value, Loans Amount						$ 15,000,000
Debt Instrument Interest Rate						15.50%
Fee payable of carrying value of the debt						1%
Percentage of carrying value of the debt paid in cash						50%
Percentage of carrying value of the debt paid in outstanding debt						50%
Net Of Debt Issuance						$ 26,464,000			26,461,000
Promissory Notes [Member] | Senior Debt
Net Of Debt Issuance						$ 0
Revenue Participation Term Notes | Senior Debt
Maturity Period						Apr. 01, 2023
Debt Instrument Interest Rate						5%
Principal And Interest Outstanding Net						$ 12,000,000
Unamortized Debt Issuance Costs						119,000
Net Of Debt Issuance						$ 11,912,000			11,915,000
Reserve Liquidity | Senior Debt
Debt Instrument Interest Rate						30%
Debt Instrument Face Amount						$ 4,000,000
Senior Debt-TEC | Promissory Notes [Member]
Maturity Period		Apr. 01, 2023	Apr. 01, 2022		Apr. 01, 2023	Apr. 01, 2023
Debt Instrument Face Amount						$ 7,200,000
Discount Issuance Costs						76,000
Debt Instrument Fee Amount	$ 100,000	$ 300,000	$ 100,000				$ 100,000			$ 100,000		$ 100,000
Extension Fee		1%	1%
Total Proceeds												100,000
Additional Borrowings First						$ 70,000
Additional Borrowings Second												60,000
Exceed Capital Expenditures	100,000					100,000
Interest Rates						14%
Principal And Interest Outstanding						$ 7,200,000
Net Of Debt Issuance						$ 7,089,000			7,095,000
Senior Debt-TEC | Reserve Liquidity Facility [Member]
Maturity Period				Apr. 01, 2023		Apr. 01, 2023
Debt Amount				$ 18,000,000
Debt Instrument Interest Rate				30%
Line Of Credit Facility, Increase (decrease), Net				$ 70,000,000
Default Event				40%
Non-refundable Fees Percentage				2%
Non-refundable Fees				$ 50,000
Reserve Liquidity Facility After Reduction		$ 40,000,000
Senior Debt-TEC | Revolving Credit Facility
Debt Amount													$ 18,000,000
Repayment Of Revolving Line						$ 16,000,000
Net Of Debt Issuance						54,039,000			75,980,000
Subordinated Notes
Debt Instrument Face Amount						$ 900,000
Debt Instrument Interest Rate						10%
Debt Instrument Fee						$ 90,000
Debt Instrument Fee, Second						$ 250,000
Debt Instrument Interest Rate						10%
Warrants Exercisable						$ 0.01
Equity Financing						$ 2,500,000
Warrants To Purchase Common Stock Shares						113,000
Principal And Interest Outstanding Net						$ 15,100,000			14,300,000
Net Of Debt Issuance						15,105,000			14,304,000
GAFI Revolving Loan
Aggregate Loan Amount						10,000,000
Cilion [Member]
Debt Instrument Face Amount						$ 6,700,000
Debt Instrument Interest Rate						3%
EB-5 Phase I Notes
Debt Instrument Face Amount						$ 500,000
Principal And Interest Outstanding Net						36,000,000
Remaining Funded To Escrow						500,000
Aggregate Principal Amount						36,000,000
Escrow Amount						35,500,000
Interest Outstanding						4,200,000
Investment Funds						$ 500,000
Conversion Price						$ 30
Accrued Interest Outstanding						$ 4,300,000			4,100,000
Principal Funding Amount						32,500,000			$ 32,500,000
Secunderabad Oils
Debt Instrument Face Amount						$ 2,300,000
Debt Instrument Interest Rate						14.75%
Monthly Net Operating Profit Rate						30%
GAFI Term loan and Revolving loan
Debt Instrument Face Amount						$ 15,000,000
Debt Instrument Interest Rate						10%
GAFI Term loan and Revolving loan | Minimum [Member]
Loan Rate						7.75%
GAFI Term loan and Revolving loan | Maximum [Member]
Loan Rate						12%
Financing Agreement for capital expenditures [Member]
Net Of Debt Issuance						$ 5,700,000
Net And The Related Liability						700,000
Other Long Term Debt						$ 4,900,000
EB-5 Phase II Notes
Debt Instrument Interest Rate						3%
Principal And Interest Outstanding Net						$ 4,000,000
Remaining Funded To Escrow						46,800,000
Aggregate Principal Amount						50,800,000
Investment Funds						500,000
Increased Debt Insrument Face Amount						$ 900,000
Due And Payable Term						5 years
Released from escrow						$ 4,000,000
Principal Amount Per						$ 0.9
Capital Revolving Credit Facility for Fuels and Carbon Lines
Term loan						$ 1,000,000
Aggregate Credit Facilities								$ 100,000,000
Purchase Shares Of Common Stock								50,000
Exercise Price								$ 10.20
Warrant Holders Purchase Of Common Stock								250,000
Warrant Exercise Price						$ 20
Number Of Shares Issued To Existing Shareholders						100,000
Short term credit facility												$ 210,000
Maturity Period						Mar. 01, 2025
Description Of Interest Rate						the greater of (i) the prime rate plus 6.00% and (ii) ten percent (10.0%), and the revolving loans made under the Carbon Revolving Line will have a maturity date of March 1, 2026 and accrue a rate of interest per annum equal to the greater of (i) the prime rate plus 4.00% and (ii) eight percent (8.0%).
Unamortized Debt Issuance Cost						$ 2,900,000
Debt Instrument Face Amount						25,100,000
Fuels Revolving Line
Unamortized Debt Issuance Cost						1,900,000
Debt Instrument Face Amount						$ 20,200,000
Debt Amount								$ 50
Carbon Revolving Line
Debt Amount								$ 50

Commitments and Contingencies_2

Commitments and Contingencies (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Operating Lease Cost
Operating Lease Expense	$ 159	$ 204	$ 347	$ 408
Short Term Lease Expense	75	71	102	110
Variable Lease Expense	23	21	46	54
Total Operating Lease Cost	257	296	495	572
Finance Lease Cost
Amortization Of Right-of-use-assets	28	55	89	110
Interest On Lease Liabilities	99	20	119	41
Total Finance Lease Cost	$ 127	$ 75	$ 208	$ 151

Commitments and Contingencies_3

Commitments and Contingencies (Details 1) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Commitments and Contingencies
Operating Cash Flows Used In Operating Leases	$ 174	$ 173	$ 338	$ 340
Operating Cash Flows Used In Finance Leases	99	20	118	41
Financing Cash Flows Used In Finance Leases	$ 50	$ 124	$ 182	$ 248

Commitments and Contingencies_4

Commitments and Contingencies (Details 2) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Commitments and Contingencies
Accretion Of The Lease Liability	$ 85	$ 96	$ 179	$ 195
Amortization Of Right-of-use Assets	74	$ 108	168	$ 213
Weighted Average Remaining Lease Term
Operating Leases		5 years 10 months 24 days		5 years 10 months 24 days
Finance Leases		14 years 1 month 6 days		14 years 1 month 6 days
Weighted Average Discount Rate
Operating Leases		14%		14%
Finance Leases		13.40%		13.40%
Operating Leases
Operating Lease Right-of-use Assets	2,294		2,294		$ 2,462
Current Portion Of Operating Lease Liability	258		258		260
Long Term Operating Lease Liability	2,191		2,191		2,318
Total Operating Lease Liabilities	2,449		2,449		2,578
Finance Leases
Property And Equipment, At Cost	3,152		3,152		2,317
Accumulated Depreciation	(72)		(72)		(376)
Property And Equipment, Net	3,080		3,080		1,941
Other Current Liability	196		196		550
Other long term liabilities	2,849		2,849		720
Total Finance Lease Liabilities	$ 3,045		$ 3,045		$ 1,270

Commitments and Contingencies_5

Commitments and Contingencies (Details 3) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Commitments and Contingencies
2023	$ 572
2024	581
2025	599
2026	617
2027	636
Thereafter	606
Total Lease Payments	3,611
Less: Imputed Interest	(1,162)
Total Operating Lease Liability	2,449	$ 2,578
2023	561
2024	279
2025	179
2026	151
2027	145
Thereafter	11,000
Total Lease Payments	12,315
Less: Imputed Interest	(9,270)
Total Finance Lease Liability	$ 3,045	$ 1,270

Commitments and Contingencies_6

Commitments and Contingencies (Details 4) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Commitments and Contingencies
Lease income	$ 377	$ 0

Commitments and Contingencies_7

Commitments and Contingencies (Details 5) $ in Thousands	Jun. 30, 2022 USD ($)
Commitments and Contingencies
2023	$ 830
2024	686
2025	541
2026	474
2027	474
Thereafter	1,303
Total future lease commitments	$ 4,308

Commitments and Contingencies_8

Commitments and Contingencies (Details Narrative) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	May 06, 2022	Mar. 03, 2022	Dec. 31, 2021	Jul. 24, 2019
Stock-Based Compensation
Remaining Term	15 years
Initial Term	12 years
Property Tax Accrual Amount			$ 6,100
Fees And Costs	$ 0			$ 6,200	$ 6,200
Settlement Aggrement, Amount		$ 4,800
Gain on litigation	$ 1,400

Aemetis Biogas LLC - Series A_2

Aemetis Biogas LLC - Series A Preferred Financing and Variable Interest Entity (Details Narrative) - USD ($)	1 Months Ended	6 Months Ended		12 Months Ended
	Dec. 20, 2018	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Totaling Of Series A Preferred Stock Unit		$ 54,900,000
Total Assets Of Abgl Company		57,800,000
Long-term Liabilities		50,300,000		$ 45,000,000
Accretion Expense		4,600,000		3,200,000
Preferred Units Redeemed Value		30,000
Preferred Units Issued Value		$ 3,100,000
Preferred Stock Unit		626,000
Preferred Units Series A [Member] | Second Tranche [Member]
Stock Redeemed Or Called During Period Shares		20,000	20,000
Reduced Redemption Shares		20,000
Preferred Stock Unit		$ 89,700,000		$ 30,000
Reduced Redemption Shares Amount		14,000,000
Preferred Units Series A [Member] | First Tranche [Member]
Preferred Stock Amunt		$ 16,000,000
Preferred Shares Issued		2,800,000
Series A Preferred Stocks [Member]
Conversion Of Common Stock Into Shares	1,200,000
Common Stock Shares	6,000,000
Per Shares	$ 5
Proceeds From Preferred Stock	$ 30,000,000
Additional Common Unit	5,000,000
Property Tax Accrual Amount		$ 0
Preferred Units Series A [Member]
Preferred Stock Unit		3,200,000
Conversion Of Common Stock Into Shares	1,200,000
Common Stock Shares	6,000,000
Redemption Unit Value		$ 3,000,000
Total Amount	$ 30,000,000
Shares Percentage	75%	75%
Redemption Payments Increased Rate		100%
Increases Payment Of Cash Flow		100%
Preferred Stock Shares Authorized	11,000,000	11,000,000
Preference Payments	$ 0.50
Maximum Number Of Shares	5,000,000
Redemption Per Share	$ 15
Cash Flow Amount	90,000,000
Paid Fees	$ 900,000
Increases Conversion Of Common Stock Units	5,000,000
Initial Rate Free Cash Flows		75%

Stock-Based Compensation (Detai

Stock-Based Compensation (Details)	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Stock-Based Compensation
Shares Available For Grant, Beginning (in Thousands)	142
Shares Available For Grant, Authorized (in Thousands)	1,338
Shares Available For Grant, Option Granted (in Thousands)	(939)
Shares Available For Grant, Rsas Granted (in Thousands)	(60)
Shares Available For Grant, Forfeited/expired	43
Shares Available For Grant, Ending (in Thousands)	524
Number Of Outstanding, Beginning (in Thousands)	3,763
Number Of Shares, Option Granted (in Thousands)	939
Number Of Shares, Exercised (in Thousands)	(266)
Number Of Shares, Forfeited/expired (in Thousands)	(43)
Number Of Outstanding, Ending (in Thousands)	4,393
Weighted Average Exercise Price Outstanding, Beginning | $ / shares	$ 2.29
Weighted Average Exercise Price, Option Granted | $ / shares	11.31
Weighted Average Exercise Price, Exercised | $ / shares	0.91
Weighted Average Exercise Price, Forfeited/expired | $ / shares	11.55
Weighted Average Exercise Price Outstanding, Ending | $ / shares	$ 4.21

Stock-Based Compensation (Det_2

Stock-Based Compensation (Details 1) - $ / shares	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Dividend-yield	0%	0%
Risk-free Interest Rate	1.45%	0.12%
Expected Volatility	139.55%	150.17%
Expected Life (years)	4 years	2 years
Stocks Option [Member]
Dividend-yield	0%	0%
Risk-free Interest Rate	0%	1.30%
Expected Volatility	0%	122.81%
Expected Life (years)		7 years
Market Value Per Share On Grant Date	$ 0	$ 13.09
Fair Value Per Option On Grant Date	$ 0	$ 11.79

Stock-Based Compensation (Det_3

Stock-Based Compensation (Details Narrative) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended		3 Months Ended		6 Months Ended	12 Months Ended
	Jan. 31, 2022	Apr. 29, 2019	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Dec. 31, 2021
Restricted Stock Granted	60,300
Price Per Restricted Share	$ 11.31
Options Granted			0	30,000
Unrecognized Compensation Expense			$ 10.4		$ 10.4
Unrecognized Compensation Expense, Recognition Period			2 years 4 months 24 days
Stock Option Shares		177,246
Common Stock, Shares Authorized (in Thousands)			80,000,000		80,000,000	80,000,000
Shares Available For Grant, Granted (in Thousands)					(939)
2019 Stock Plan [Member]
Restricted Stock Granted						120,000
Options Granted	932,800
Unrecognized Compensation Expense					2,600,000
Common Stock, Shares Authorized (in Thousands)			200,000		200,000
Shares Available For Grant, Granted (in Thousands)						1,140,000
Vesting Terms						3 years
Stock Plan Term						10 years

Outstanding Warrants (Details)

Outstanding Warrants (Details) - $ / shares	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Outstanding Warrants
Dividend Yield	0%	0%
Risk-free Interest Rate	1.45%	0.12%
Expected Volatility	139.55%	150.17%
Expected Life (years)	4 years	2 years
Exercise Price Per Warrant	$ 13.33	$ 0.01
Market Value Per Share On Grant Date	13.06	2.49
Fair Value Per Share On Grant Date	$ 11.01	$ 2.48

Outstanding Warrants (Details 1

Outstanding Warrants (Details 1) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Number Of Warrants Granted	939
Weighted Average Exercise Price Outstanding, Beginning	$ 2.29
Weighted Average Exercise Price Granted	11.31
Weighted Average Exercise Price Exercised	0.91
Weighted Average Exercise Price Outstanding, Ending	$ 4.21	$ 2.29
Warrants
Number Of Outstanding, Beginning	55	95
Number Of Warrants Granted	413	292
Number Of Warrants Exercised	(113)	(332)
Number Of Outstanding, Ending	355	55	95
Weighted Average Exercise Price Outstanding, Beginning	$ 2.59	$ 2.59
Weighted Average Exercise Price Granted	13.33	0.01
Weighted Average Exercise Price Exercised	0.01	0.32
Weighted Average Exercise Price Outstanding, Ending	$ 15.92	$ 2.59	$ 2.59
Weighted Average Remaining Contractual Life (in Years) Outstanding, Ending	7 years 11 months 26 days	3 years 11 months 12 days	4 years 11 months 12 days

Agreements (Details)

Agreements (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Agreements (Details)
Wet Distiller's Grains Sales	$ 15,150	$ 10,630	$ 26,666	$ 21,665
Corn Oil Sales	2,812	1,695	5,150	2,737
Corn Purchases	54,352	42,166	98,362	80,159
Accounts Receivable	232	65	232	65
Accounts Payable	$ 612	$ 509	$ 612	$ 509

Agreements (Details Narrative)

Agreements (Details Narrative) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Marketing Costs	$ 0.8	$ 0.7	$ 1.5	$ 1.4
J. D. Heiskell [Member]
Prepayments	1.7		1.7		$ 4
Accounts Receivable	$ 0.6		$ 0.6		$ 1.2

Segment Information (Details)

Segment Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Sales	$ 65,901,000	$ 54,884,000	$ 117,950,000	$ 97,691,000
Intersegment Revenues	297,000	694,000	632,000	735,000
Gross Profit (loss)	(214,000)	3,646,000	(3,299,000)	38,000
Interest Expense	6,668,000	5,219,000	12,929,000	12,399,000
Accretion And Other Expenses Of Series A Preferred Units	1,506,000	3,800,000	3,146,000	5,743,000
Capital Expenditures	13,059,000	6,375,000	22,518,000	12,935,000
Depreciation	1,325,000	1,378,000	2,661,000	2,764,000
Total Assets	178,452,000	143,287,000	178,452,000	143,287,000	$ 160,831,000
Interest Expense	4,928,000	4,529,000	9,363,000	10,494,000
India Biodiesel
Sales	10,000	154,000	18,000	633,000
Intersegment Revenues	0	0	0	0
Gross Profit (loss)	10,000	(15,000)	18,000	(70,000)
Accretion And Other Expenses Of Series A Preferred Units	0	0	0	0
Capital Expenditures	69,000	1,000	136,000	118,000
Depreciation	164,000	174,000	332,000	358,000
Total Assets	9,324,000	12,306,000	9,324,000	12,306,000
Interest Expense	0	0	0	0
All Others
Sales	0	0	0	0
Intersegment Revenues	0	0	0	0
Gross Profit (loss)	(4,000)	(38,000)	(10,000)	(48,000)
Accretion And Other Expenses Of Series A Preferred Units	0	0	0	0
Capital Expenditures	928,000	3,104,000	3,068,000	5,147,000
Depreciation	30,000	12,000	41,000	20,000
Total Assets	46,817,000	26,715,000	46,817,000	26,715,000
Interest Expense	1,792,000	230,000	2,404,000	1,708,000
California Ethanol
Sales	65,891,000	54,730,000	117,932,000	97,058,000
Intersegment Revenues	0	0	0	0
Gross Profit (loss)	(152,000)	3,372,000	(3,032,000)	241,000
Accretion And Other Expenses Of Series A Preferred Units	0	0	0	0
Capital Expenditures	5,366,000	767,000	7,169,000	775,000
Depreciation	977,000	1,050,000	1,988,000	2,102,000
Total Assets	66,580,000	76,452,000	66,580,000	76,452,000
Interest Expense	4,869,000	4,986,000	10,514,000	10,685,000
Dairy Renewable Natural Gas
Sales	0	0	0	0
Intersegment Revenues	297,000	694,000	632,000	735,000
Gross Profit (loss)	(68,000)	327,000	(275,000)	(85,000)
Accretion And Other Expenses Of Series A Preferred Units	1,506,000	3,800,000	3,146,000	5,743,000
Capital Expenditures	6,696,000	2,503,000	12,145,000	6,895,000
Depreciation	154,000	142,000	300,000	284,000
Total Assets	55,731,000	27,814,000	55,731,000	27,814,000
Interest Expense	$ 7,000	$ 3,000	$ 11,000	$ 6,000

Segment Information (Details 1)

Segment Information (Details 1) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Segment Information
Total Revenues For Reportable Segments	$ 66,198	$ 55,578	$ 118,582	$ 98,426
Elmination Of Intersegment Revenues	(297)	(694)	(632)	(735)
Total Consolidated Revenues	$ 65,901	$ 54,884	$ 117,950	$ 97,691

Segment Information (Details Na

Segment Information (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Gallon Per Year			$ 90,000,000
India Biodiesel
Gallon Per Year			50,000,000
California Ethanol
Gallon Per Year			$ 65,000,000
California Ethanol | Sales of ethanol, WDG, and corn oil
Concentration Credit Risk	72%	77%	72%	74%
Concentration Credit Risk, Two	27%	23%	27%	25%

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)		3 Months Ended		6 Months Ended		12 Months Ended
	Nov. 04, 2021	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Guaranty Fees	$ 400,000			$ 2,000,000
Other Expenses				400,000
Pre Payment Other				200,000
Eric McAfee and McAfee Capital
Remaining Expenses				100,000
Prepaid Expense		$ 20,000		20,000
Accrued Liability		10,000		$ 10,000		$ 300,000
Issued For Common Shares				180,000
Various Board Members
Related Party Transaction				$ 20,000		$ 200,000
Board Compensation Fees		$ 100,000	$ 100,000	$ 200,000	$ 200,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($) $ / shares in Units, $ in Millions			6 Months Ended
	Aug. 08, 2022	Jul. 01, 2022	Jun. 30, 2022
Warrants to purchase common stock			939
Exercise price			$ 11.31
Subsequent Event
Loan repayment	$ 7.3
Redemtion of units, amount one	116
Redemtion of units, amount two	$ 106
Subsequent Event | Note Purchase Agreement [Member]
Cash extension fee	1%
Waiver fee	$ 0.3
Subsequent Event | Subordinated Debt Refinancing [Member]
Cash extension fee		10%
Equity financing		$ 25
Warrants to purchase common stock		113,000
Exercise price		$ 0.01